

Developing a Science- and Risk-Based Bio-decontamination Control Strategy for Pharmaceutical Isolators

Lifecycle Framework Linking Regulatory Expectation, Microbial Science, Technology Selection, Validation and Continued Verification

Contents

Executive Summary	3
1. Introduction: Why Bio-decontamination Matters	3
1.1 The Contamination Pathway	3
1.2 Why Barrier Systems Alone Are Not Enough	5
1.3 Purpose of Paper	5
2. Regulatory Evolution: How's the Expectation Has Changed	5
2.1 FDA Expectations	6
2.2 EU GMP Annex 1 (2022), PIC/S PE 009 and WHO TRS 1044 Annex 2	6
2.3 Comparative Summary	7
3. Decontamination Within the Contamination Control Strategy	7
3.1 The Interacting Control Chain	8
3.2 A Practical CCS Framework for Bio-decontamination	8
<ul style="list-style-type: none"> • Risk Assessment • Cleaning and Disinfection Strategy • Bio-decontamination Process Design • Validation: Demonstrating Process Capability • Routine Monitoring • Periodic Review 	
3.3 CCS as a Living System	10
4. Fundamentals of Bio-decontamination Science	11
4.1 Surface Bio-decontamination and Selection of Decontamination Agents	11
4.2 Mechanism of Hydrogen Peroxide Microbial Inactivation	11
4.3 D-value, Log Reduction, and the Rationale for Biological Indicators	12
5. Bio-decontamination Technologies Around Hydrogen Peroxide	12
5.1 Vaporized Hydrogen Peroxide (VHP)	12
<ul style="list-style-type: none"> • VHP Principle • Factors Influencing VHP Effectiveness • Advantages and Limitations 	

5.2 Atomized Hydrogen Peroxide (AHP)	15
• AHP Principle	
• Factor Influencing AHP	
• Application and Limitations	
5.3 Nebulized Hydrogen Peroxide (NHP)	16
• Principle	
• Factors Affecting Performance	
• Applications	
• Limitations	
5.4 Comparative Summary	18
6. Developing a Decontamination Cycle	19
6.1 The Typical Cycle Structure	20
6.2 How Parameters Interact	20
6.3 Worst-Case Development	22
• Worst-Case Load Versus Full Load and Empty Load	
6.4 Hydrogen Peroxide Desorption and Residue	25
6.4.1 Sorption During Decontamination as the Origin of Residues	
6.4.2 Desorption Kinetics and the Aeration Endpoint	
6.4.3 Risk to Product and Process	
6.4.4 Risk Management of Residues	
7. Validation Strategy	26
7.1 Qualification Framework (IQ/OQ/PQ)	26
7.1.1 Pre-Cycle Prerequisites, Sequence, and Interlocks	
7.2 Cycle Development Within Validation	27
7.3 Biological Indicators	27
7.4 Chemical Indicators	28
7.5 Emerging: Enzymatic Indicators	29
8. Routine Performance Monitoring	31
8.1 Routine Biological Indicator Challenge Frequency	31
8.2 Periodic Requalification	31
8.3 Cycle Trending	31
8.4 Alarm Management	32
8.5 Environmental Monitoring	33
8.6 Deviation Handling	33
8.7 Change Control	33
8.8 Maintenance, Calibration, and Sensor Verification	34
9. Practical Recommendation	34
9.1 Define the Contamination-Control Requirements Before Selecting the Technology	34
9.2 Select VHP, AHP, or NHP According to the Application	35
9.3 Design and Validate Against the Worst Case	36
9.4 Treat the Load Configuration as Part of the Validated Process	36
9.5 Develop the Cycle as a Process, Not a Fixed Recipe	36
9.6 Establish the Aeration Endpoint Using All Relevant Acceptance Criteria	37
9.7 Use Indicators as Complementary Tools With Clearly Defined Roles	37
9.8 Monitor the Process, Not Just the Biological Result	37
9.9 Treat Instrumentation as Part of the Validation System	38
9.10 Make Change Control Part of the Bio-decontamination Strategy	38
9.11 Establish a Lifecycle Review Rather Than a One-Time Validation	38
9.12 The Manufacturer's Practical Checklist	38
10. Conclusion	39
11. References	39

Executive Summary

Bio-decontamination has evolved from peripheral utility step to a central pillar of sterility assurance. The convergence of three forces: the 2022 revision of EU GMP Annex 1, the industry-wide shift toward barrier technologies, and growing regulatory demand on a documented, lifecycle-based Contamination Control Strategy (CCS), has fundamentally changed how pharmaceutical manufacturers must think about decontamination processes.

Historically, bio-decontamination was treated as an isolated utility cycle: a validated "run" of a typical hydrogen peroxide exposure performed between batches or campaigns, qualified once and monitored loosely thereafter. That model is no longer sufficient. Annex 1 explicitly requires integrated holistic CCS that links facility design, premises and equipment, personnel, utilities, raw material including product containers and closures controls, process risk and validation, preventative maintenance, cleaning, disinfection (including bio-decontamination), monitoring systems, prevention mechanism and periodic review into a single, risk-based, continuously improving system [1].

This white paper presents a science- and risk-based framework for bio-decontamination that follows the natural lifecycle of contamination control rather than a purely technical sequence. It is organized around questions that a manufacturer, quality unit, or regulator commonly consider:

- Why does bio-decontamination matter, and what does the regulatory landscape now expect? (Regulatory Evolution)
- What is actually happening at the microbial level, and what governs whether a cycle achieves the required log reduction? (Fundamentals)
- How should a technology be selected and a cycle designed for a specific application? (Technology and Cycle Development)
- How is this proven to work, reproducibly, at worst case? (Validation Strategy)
- How is the validated state maintained over the operational life of the equipment? (Routine Monitoring)

The paper concludes with a set of practical recommendations intended to be directly actionable by engineering, quality, and validation functions. The central argument of this paper is quite simple: bio-decontamination cannot be validated, monitored, or improved in isolation. It is one interacting node within a broader contamination control system, and it must be designed, justified, and reviewed as such.

1. Introduction: Why Bio-decontamination Matters

Sterility assurance for aseptically processed products rests on the principle that risk is reduced at every point where a contamination pathway could reach the product. In conventional cleanrooms, that pathway runs primarily through personnel. Motionless operator releases approximately $\sim 10,000 \geq 0.3\mu\text{m}$ particles per minute, while slow walk releases up to $500,000+ \geq 0.3\mu\text{m}$ particles per minute with standard coverall in cleanroom [2]. Gowning breaches, glove integrity failures, and simple human movement are the dominant sources of viable and non-viable particulate contamination in classified environments. This is precisely the risk that isolators, RABS, and closed vial/syringe filling lines are designed to interrupt, by physically separating personnel from the critical zone.

Barrier technology, however, is only as effective as the decontamination process applied to it. An isolator that has not been adequately and reproducibly decontaminated before use provides a false sense of security: the physical barrier is present, but the microbiological barrier is not. This makes biodecontamination a critical element of barrier-system qualification and contamination control, requiring a scientifically justified, validated, and maintained process appropriate to its intended use

1.1 The Contamination Pathway

Maintaining sterility during aseptic manufacturing depends on understanding how contamination enters and propagates throughout the manufacturing process. Contamination should not be viewed as a single event, but rather as a continuous pathway in which microorganisms and particulate matter are transferred through personnel, materials, equipment, and process activities before ultimately reaching the sterile product. Consequently, contamination control is achieved by interrupting this pathway at multiple stages rather than relying on a single intervention.

Every object introduced into a classified manufacturing environment carries an inherent contamination burden. Components, raw materials, equipment, tools, and consumables are typically prepared in environments of lower cleanliness classification before being transferred into higher-grade cleanrooms or barrier systems. Likewise,

personnel entering controlled environments continuously generate particles originating from skin, hair, clothing, and respiratory activities despite the use of appropriate gowning systems.

The extent to which contamination presents a risk depends on both the cleanliness classification and the engineering controls of the manufacturing environment [3]. While modern cleanrooms employ high-efficiency particulate air (HEPA) filtration, controlled airflow patterns, pressure cascades, and personnel gowning to minimize contamination, these measures primarily reduce the introduction and transport of contaminants rather than completely eliminating them. Studies have shown that operator activity remains one of the largest contributors to particle generation within cleanrooms. The generation of particles $\geq 5 \mu\text{m}$ increases substantially with operator movement [4], and these larger particles are particularly significant because microorganisms are commonly associated with skin flakes, textile fibers, and other particulate matter that serve as carriers or "rafts" for microbial transport. Larger particles also possess higher settling velocities, increasing the probability of deposition onto critical surfaces and exposed sterile product. Reported studies indicate that the ratio of inert particles $\geq 5 \mu\text{m}$ to viable microorganism-carrying particles is approximately 210:1, with operators wearing conventional cleanroom garments dispersing hundreds of particles per minute during routine activities [5,6]. The contamination challenge therefore increases with every material transfer and human intervention, making ingress points one of the most critical aspects of Contamination Control Strategy (CCS).

Although personnel are frequently recognized as the primary contamination source, material ingress represents an equally important pathway that requires systematic control. Every transfer from a lower-grade environment to a higher-grade environment introduces uncertainty regarding the microbial status of external surfaces. Consequently, pharmaceutical facilities employ a series of progressively stringent contamination reduction measures according to the cleanliness requirements of each transfer stage.

Surface disinfection is generally applied during transfers into controlled environments to reduce the microbial burden present on accessible external surfaces. The effectiveness of disinfection, however, depends on several factors, including disinfectant selection, concentration, contact time, application technique, and direct surface accessibility. Areas that are shadowed, enclosed, or geometrically complex may receive inadequate disinfectant exposure, while resistant microbial spores can survive conventional disinfection procedures.

For transfers into Grade A barrier systems such as isolators, Restricted Access Barrier Systems (RABS), or other enclosed aseptic processing equipment, surface disinfection alone may not provide sufficient assurance of sterility. Instead, bio-decontamination using validated vaporized, nebulized or atomized bio-decontamination agents is employed to achieve a substantially greater reduction of microbial contamination across all exposed internal surfaces. Unlike manual disinfection, bio-decontamination enables the active agent to be distributed throughout an enclosed space, including surfaces that may be difficult to access manually, provided that the delivery system and cycle are appropriately designed and validated.




Figure 1. The contamination pathway during aseptic manufacturing.

Accordingly, bio-decontamination should not be considered an isolated step, but rather one component within a comprehensive contamination control strategy. Its primary function is to interrupt the contamination pathway after materials and equipment have entered the barrier system but before aseptic processing begins, thereby minimizing the probability that residual microorganisms present on internal surfaces become a source of product contamination.

1.2 Why Barrier Systems Alone Are Not Enough

Isolators and RABS reduce the frequency and severity of personnel-related interventions, and in the case of closed isolators, largely eliminate direct human access to the critical zone during operation. But every barrier system has an opening state at some point in its lifecycle: initial setup, component and material loading, glove and sleeve changes, maintenance interventions, and transfer through mouseholes, rapid transfer ports (RTPs), or airlocks. Each of these events reintroduces bioburden risk that must be addressed before the space is returned to the required qualified state.

Consequently, the regulatory and scientific community no longer views bio-decontamination as a discrete utility cycle to be validated once and monitored loosely. This makes bio-decontamination a critical element of barrier-system qualification and contamination control, requiring a scientifically justified, validated, and maintained process appropriate to its intended use.

1.3 Purpose of Paper

This paper provides a practical, science- and risk-based framework for developing, validating, and maintaining hydrogen peroxide bio-decontamination processes for closed barrier systems. It aims to support consistent decision-making from technology selection and cycle development through qualification, routine monitoring, and lifecycle management.

In this paper, “bio-decontamination” refers to a validated process intended to achieve a defined reduction of viable microorganisms on exposed surfaces within a closed or barrier system. The terms “sterilization,” “sterilant,” and “sterile” are used only where specifically supported by the applicable regulatory, pharmacopeial, or process context.

2. Regulatory Evolution: How’s the Expectation Has Changed

Understanding current expectations requires understanding how they develop. Bio-decontamination guidance has evolved over roughly two decades from general aseptic processing principles toward highly specific, lifecycle-oriented requirements embedded within a mandatory contamination control strategy.

Evolution of Regulatory Guidance for Isolators and Barrier Systems for Aseptic Processing and Sterile Manufacturing




Figure 2. Approximate timeline of regulatory and technical guidance shaping bio-decontamination expectations

2.1 FDA Expectations

The U.S. Food and Drug Administration (FDA) established the foundational regulatory framework for aseptic barrier systems in its *Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice* (2004). Although the guidance does not prescribe a specific bio-decontamination technology, it establishes the foundational expectations for validated decontamination of isolators. Modern lifecycle management concepts are subsequently reinforced by broader GMP and quality-system expectations.

FDA's approach is fundamentally performance- and science-based rather than prescriptive. Manufacturers are expected to demonstrate, through qualification and validation, that the selected bio-decontamination process consistently achieves the intended level of microbial reduction under representative or worst-case conditions, and that the validated state is maintained through routine monitoring, change control, and periodic requalification. The guidance does not mandate specific cycle parameters, hydrogen peroxide concentrations, exposure times, or biological indicator populations; instead, these should be supported by scientific rationale and validation data.

Appendix 1, Aseptic Processing Isolators under Section D. Decontamination, provides practical recommendations for implementing and validating bio-decontamination processes [7], including:

- Cleaning should be completed prior to the bio-decontamination cycle to remove residues that may reduce sporicidal efficacy.
- Glove extenders or equivalent devices should be used to separate glove fingers and improve sterilant exposure to all glove surfaces.
- Vaporized sterilants are specifically recognized as suitable agents for isolator bio-decontamination.
- Decontamination cycle development and qualification should be supported using appropriate biological indicators (BI) and chemical indicators (CI).
- The required microbial reduction should be justified according to the intended application. As an example, FDA notes that a 4-log reduction may be sufficient for very low-bioburden materials introduced through transfer isolators (e.g., wrapped sterile components briefly exposed to the surrounding cleanroom), whereas higher reductions (e.g., 6-log reduction) may be appropriate for other applications.
- Any confirmed breach of isolator integrity should trigger an appropriate investigation and, where product protection cannot be assured, re-bio-decontamination before further aseptic processing.

Overall, the FDA guidance establishes the key principle that bio-decontamination is not a fixed cycle or technology, but a validated and continuously controlled process that should be appropriate for the intended aseptic application and supported by scientific evidence.

2.2 EU GMP Annex 1 (2022), PIC/S PE 009 and WHO TRS 1044 Annex 2

The publication of EU GMP Annex 1: Manufacture of Sterile Medicinal Products (2022) represents the most significant regulatory evolution affecting bio-decontamination in recent years. While the FDA's 2004 aseptic processing guidance established the scientific principles for decontamination validation, Annex 1 expands these expectations by positioning bio-decontamination within a holistic Contamination Control Strategy (CCS) that spans the entire manufacturing lifecycle.

Rather than treating bio-decontamination solely as an equipment qualification activity, Annex 1 implies that it should be developed, validated, routinely verified, periodically reviewed, and managed through a risk-based quality system. The validated state should be maintained throughout the operational lifecycle, with any changes that may affect decontamination efficacy, such as modifications to chamber configuration, load patterns, transfer devices, or operating conditions being formally assessed through change control and, where appropriate, requalification.

These principles are closely harmonized with PIC/S PE 009-17 Annex 1, which adopts equivalent expectations for sterile manufacturing facilities. Similarly, WHO Technical Report Series (TRS) 1044 Annex 2 was developed through international regulatory collaboration and is broadly aligned with both EU GMP Annex 1 and PIC/S guidance, promoting consistent approach globally to aseptic manufacturing and contamination control.

Across these three guidance documents, the following expectations for bio-decontamination are explicitly emphasized:

- A documented Contamination Control Strategy (CCS) should identify bio-decontamination as one of the risk control measures for aseptic processing.
- Cleaning should be completed before the bio-decontamination cycle, as residues and organic contamination may reduce sporicidal efficacy.
- Bio-decontamination processes should be automated, validated, and performed within predefined and controlled cycle parameters using a suitable sporicidal agent, typically in gaseous or vaporized form.

- Gloves should be positioned with fingers separated during bio-decontamination to facilitate uniform sterilant exposure to all glove surfaces.

Compared with earlier regulatory guidance, Annex 1 and its harmonized counterparts clearly shift the industry's perspective from validating a bio-decontamination cycle to managing bio-decontamination as a continuously controlled process within an integrated Contamination Control Strategy. This lifecycle approach forms the basis for modern bio-decontamination practices in pharmaceutical barrier systems.

2.3 Comparative Summary

Requirement	FDA Aseptic Guidance (2004)	EU GMP Annex 1, PIC/S PE 009 and WHO TRS 1044 Annex 2 (2022)
Regulatory status	Binding guidance (US)	Binding GMP annex (EU)
CCS requirement	Implied / expected	Explicit, mandatory, documented
Bio-decontamination validation	Required, principle-based	Required, more prescriptive
Routine monitoring	Expected	Explicit trending & periodic review
Technology prescription	None, justify scientifically	None, justify scientifically

3. Decontamination Within the Contamination Control Strategy

The modern approach to bio-decontamination has evolved from viewing it as an isolated equipment qualification activity into recognizing it as an integrated component of a broader Contamination Control Strategy (CCS). Under current regulatory expectations, successful bio-decontamination cannot be demonstrated solely by achieving a predefined microbial reduction during validation; rather, its effectiveness depends on how it interacts with facility design, engineering controls, cleaning practices, environmental monitoring, and operational discipline.

A fundamental principle of CCS is that sterility assurance is achieved through the combined effectiveness of multiple, mutually reinforcing control measures rather than through a single intervention. Each contamination control measure addresses a specific contamination mechanism and has inherent capabilities and limitations. Therefore, bio-decontamination should not be considered a replacement for other contamination controls, nor should the performance of other controls compensate for an ineffective bio-decontamination process.

Control	Primary Purpose	Does it kill microorganisms?
HVAC	Prevent particle ingress	No
Barrier System	Separate personnel	No
Cleaning	Remove soils and residues	Limited
Disinfection	Reduce vegetative microorganisms	Partially
Bio-decontamination	Inactivate resistant spores in enclosed surfaces	Yes
Environmental monitoring	Verify state of control	No
APS	Demonstrate process capability	No

A validated bio-decontamination cycle provides assurance that resistant microorganisms can be effectively reduced under defined conditions; however, it does not eliminate the need for appropriate facility design, effective cleaning procedures, validated transfer processes, or continuous monitoring of the manufacturing environment. Conversely, strong engineering controls cannot compensate for insufficient bio-decontamination of surfaces that may become part of the aseptic processing environment. Sterility assurance is therefore dependent on maintaining control across the entire contamination pathway.

3.1 The Interacting Control Chain

The relationship between bio-decontamination and other contamination controls can be understood as an interconnected chain of preventive, verification, and corrective measures throughout the manufacturing lifecycle.

Consider everything that must function correctly for a barrier system to deliver sterility assurance on a given day of production. Facility design and HVAC establish the pressure cascade and air quality that the barrier operates within. The barrier system itself defines physical separation from personnel. Cleaning removes gross soil and organic residue. Disinfection reduces surface bioburden using sporicidal or non-sporicidal agents as part of routine housekeeping. Bio-decontamination achieves the validated log reduction of resistant spore-forming organisms across the entire interior surface, including hard-to-reach geometry. Environmental monitoring then verifies, on an ongoing basis, that the qualified state has been maintained. Aseptic process simulation (APS) periodically challenges the entire system, including bio-decontamination, under simulated worst-case conditions. Any deviation from expected performance is investigated, and the resulting data are trended over time to detect drift before it becomes a failure.




Figure 3. The interacting control chain. Bio-decontamination is one link among many; a failure or drift anywhere in the chain can mask a bio-decontamination-related finding.

A key implication of this integrated approach is that contamination events cannot always be attributed directly to bio-decontamination performance. For example, an environmental monitoring breach, failed APS, or recurring contamination event may be associated with inadequate bio-decontamination cycle performance; however, the root cause may equally originate from other factors, including compromised barrier integrity, deterioration of HEPA filtration performance, ineffective cleaning practices, inadequate disinfectant application, poor material transfer control, increased incoming bioburden, or inappropriate operator practices.

Therefore, contamination investigations should evaluate the complete control strategy rather than focusing on a single process step. A CCS-based approach requires manufacturers to assess the interaction between engineering controls, procedural controls, monitoring data, and bio-decontamination performance to determine whether the system remains in a state of control.

3.2 A Practical CCS Framework for Bio-decontamination

Within the broader contamination control strategy, bio-decontamination should be managed as an independent but interconnected lifecycle process. A validated bio-decontamination cycle is not simply a function of decontaminating agent delivery and exposure. A practical bio-decontamination control framework can be represented as:

Risk Assessment

Risk assessment represents the foundation of bio-decontamination design. The objective is not merely to select a sterilant, but to define the contamination challenge that the process must control. Before selecting a bio-decontamination technology, manufacturers should evaluate application risk starting with below example questions.

What is the intended application?

- a.) Sterility testing isolator?
- b.) Aseptic processing isolator?
- c.) Filling isolator?
- d.) Material transfer chamber?
- e.) RABS?

What is the consequence of contamination?

- a.) Product exposure?
- b.) Operator exposure?
- c.) Cross-contamination risk?

What microbial reduction target is scientifically justified?

What will the operational conditions be?

- a.) Maximum, typical and minimum loading configuration?
- b.) Material compatibility?
- c.) Maximum cycle duration?
- d.) Production frequency?
- e.) Recovery time requirements?
- f.) Temperature and humidity operating range?



Figure 4. Lifecycle framework for bio-decontamination control within a Contamination Control Strategy.

Cleaning and Disinfection Strategy

All regulatory documents mentioned in Section 2 emphasized bio-decontamination performance begins before sterilant is introduced by mandating cleaning to be done prior. Cleaning establishes the condition required for successful microbial inactivation. Cleaning removes organic residues, particulate contamination and residues that may protect microorganisms. Disinfection reduces routine microbial burden and provides ongoing contamination control during operation. Without effective cleaning, bio-decontamination may be compromised because residual organic materials can consume or shield microorganisms from the active sterilant.

Bio-decontamination Process Design

Following completion of the risk assessment, the bio-decontamination process should be designed to consistently achieve the intended microbial reduction while remaining compatible with the equipment, process, and manufacturing operation. Process design extends beyond selecting a sterilant; it includes defining the sterilant delivery method, injection strategy, conditioning requirements, exposure parameters, aeration method, and acceptance criteria that collectively ensure reproducible decontamination performance. The selected process should be scientifically justified based on the intended application and supported by an understanding of microbial inactivation kinetics, equipment characteristics, and process constraints.

Process design should also account for engineering factors that influence sterilant distribution and efficacy. Chamber geometry, internal equipment configuration, load arrangement, glove assemblies, transfer devices, and shadowed surfaces may all affect sterilant penetration and contact. Likewise, operational considerations such as cycle duration, production throughput, material compatibility, and operator workflow should be incorporated into the design. By integrating both microbiological and engineering principles, bio-decontamination becomes a robust, reproducible process rather than simply the execution of a predefined cycle.

Validation: Demonstrating Process Capability

Validation provides documented evidence that the designed bio-decontamination process is capable of consistently achieving its intended level of microbial inactivation under representative or worst-case conditions. Qualification should demonstrate not only that the required microbial reduction is achieved, but also that sterilant distribution, exposure, and aeration remain reproducible across the qualified operating range. Validation therefore establishes the scientific basis for routine operation by confirming that the process performs as intended under defined conditions.

A comprehensive validation strategy typically includes installation and operational qualification, cycle development studies, biological indicator (BI) challenge testing, chemical indicator (CI) assessment, and verification of critical process parameters. Particular attention should be given to identifying worst-case locations, complex geometries, and load configurations that may limit sterilant penetration. While successful validation demonstrates process capability at the time of qualification, it should be regarded as the foundation for ongoing process control rather than evidence that continued performance can be assumed indefinitely.

Routine Monitoring

Routine monitoring provides continuing assurance that the validated bio-decontamination process remains in a state of control throughout normal manufacturing operations. Unlike validation, which demonstrates process capability under defined conditions, routine monitoring confirms that each production cycle is executed within the validated operating window. Critical process parameters such as sterilant concentration, temperature, relative humidity, exposure time, aeration performance, and system alarms should be continuously monitored and reviewed to verify compliance with approved cycle specifications.

Routine monitoring should be integrated with the broader contamination control strategy by considering information from environmental monitoring, equipment maintenance, calibration activities, and operational performance. Trending cycle data over time enables manufacturers to identify gradual process drift, equipment deterioration, or abnormal operating conditions before they compromise decontamination effectiveness. Consequently, routine monitoring functions as an early warning system that supports proactive maintenance of the validated state.

Periodic Review

Bio-decontamination should be periodically reviewed to confirm that the original validation assumptions remain appropriate throughout the operational lifecycle of the equipment. Changes to chamber configuration, process equipment, load patterns, transfer devices, operating conditions, or manufacturing practices may alter the original contamination challenge and potentially affect bio-decontamination performance. Periodic review therefore provides a structured mechanism for evaluating whether the validated process continues to deliver the required level of microbial control.

The review should incorporate data from routine monitoring, environmental monitoring trends, deviation investigations, maintenance records, change control activities, and requalification studies where applicable. Rather than focusing solely on individual cycle results, the objective is to assess the overall performance of the bio-decontamination process as part of the Contamination Control Strategy. Where evidence indicates process drift or changes to critical assumptions risk assessment, process optimization, or revalidation, should be undertaken to ensure the validated state is maintained.

3.3 CCS as a Living System

A CCS should be treated as a lifecycle system rather than a static collection of controls. For biodecontamination, initial qualification establishes that the selected process can achieve its intended performance under defined conditions; however, continued control depends on maintaining the assumptions, equipment, materials, operating conditions, and contamination-control measures on which that qualification was based.

Consequently, biodecontamination should be managed within the broader CCS through appropriate ongoing monitoring, maintenance, change control, periodic review, and requalification where justified. The purpose of this lifecycle approach is not to repeatedly revalidate a process without cause, but to ensure that changes or emerging trends are recognized and evaluated before they compromise the established state of control.

4. Fundamentals of Bio-decontamination Science

4.1 Surface Bio-decontamination and Selection of Decontamination Agents

Surface bio-decontamination is an important control strategy for isolators, RABS, pass-through chambers, and other closed pharmaceutical environments where conventional manual cleaning may not reliably reach every exposed surface. An effective surface bio-decontamination process should provide broad-spectrum microbial inactivation, including bacterial spores, while achieving reproducible distribution across difficult-to-access areas and maintaining acceptable compatibility with the equipment and materials. Available chemical approaches include hydrogen peroxide (H_2O_2), peracetic acid (PAA), formaldehyde, chlorine-based agents, and other oxidizing or aldehyde-based disinfectants. The choice therefore involves balancing microbiological efficacy with penetration/distribution, material compatibility, operator safety, residues, and cycle time. Hydrogen peroxide has attracted significant attention because it enables treatment of enclosed spaces and has demonstrated activity against a broad range of microorganisms, including highly resistant bacterial spores [21].

Peracetic acid (PAA) is a strong oxidizing biocide with broad-spectrum and rapid antimicrobial activity and can be highly effective against bacterial spores [22]. However, its conventional application is primarily as an aqueous solution, making complete and uniform treatment of enclosed, complex geometries more challenging than with a gaseous or aerosolized approach. PAA is also highly irritating and can be corrosive to certain materials, which limits its suitability for some automated enclosed-space applications [23]. Formaldehyde, historically used for room and equipment fumigation, also provides broad antimicrobial activity, but its carcinogenicity and toxicity have substantially reduced its attractiveness for modern pharmaceutical and healthcare applications. Formaldehyde can also have limitations related to penetration, residuals, and the additional controls required to protect operators from exposure.

In comparison, hydrogen peroxide provides a particularly attractive overall balance for enclosed pharmaceutical bio-decontamination. It can be delivered as a vapor or aerosol to achieve non-contact treatment of complex surfaces, while its decomposition primarily produces water and oxygen, leaving substantially less persistent chemical residue than many alternative agents. Hydrogen peroxide also avoids the carcinogenicity concerns associated with formaldehyde and, when appropriately controlled, offers favorable material compatibility. Its established use, demonstrated sporicidal capability, relatively straightforward aeration, and increasing regulatory and industry familiarity have made hydrogen peroxide one of the leading technologies for automated bio-decontamination of isolators and other closed systems.

4.2 Mechanism of Hydrogen Peroxide Microbial Inactivation

Vapor- and aerosol-phase hydrogen peroxide inactivates microorganisms primarily through oxidative damage. Hydrogen peroxide generates reactive oxygen species (ROS). ROS are chemically reactive molecules containing oxygen that are generated in biological defense systems as part of the immunological response to invading bacteria [8]. Additionally, H_2O_2 can be converted into hydroxyl radical ($\text{HO}\cdot$) by the Fenton [9] and Haber-Weiss [10] reactions. $\text{HO}\cdot$ is also a ROS and has one unpaired electron in its structure, so it is apt to remove an electron from other substances, thereby oxidizing them [11]. This makes $\text{HO}\cdot$ reactive and toxic to bacteria because it oxidizes sulfhydryl groups and double bonds in proteins, lipids, and membrane surfaces.

In vegetative cells this causes rapid loss of membrane integrity and cell death. Bacterial endospores, which are the target organism of concern for validation purposes, are substantially more resistant due to their dehydrated core, protective coat proteins, and dipicolinic acid content, which limits penetration of the oxidizing agent to the spore core. Inactivation of spores proceeds through progressive damage to the spore coat and inner membrane, followed by penetration and damage to core enzymes and DNA, and ultimately loss of the ability to germinate and outgrow.

Importantly, the physical state of H_2O_2 can influence its interaction with biological materials. Finnegan et al. [18] reported differences between liquid- and vapor-phase H_2O_2 in their interaction with biomolecules. Liquid H_2O_2 was able to oxidize several amino acids, including cysteine, methionine, lysine, histidine, and glycine, whereas vapor-phase H_2O_2 did not show the same oxidation behavior under the conditions investigated. Conversely, vapor-phase H_2O_2 was capable of completely degrading proteins such as aldolase and bovine serum albumin (BSA), while no comparable effect was observed with liquid-phase H_2O_2 [18]. Similar observations were reported by McDonnell [19] in studies of bacterial protein toxins, further demonstrating that vapor- and liquid-phase H_2O_2 may interact differently with biological targets. Linley [20] also investigated damage to multiple macromolecular targets in *E. coli* following exposure to both forms of H_2O_2 . These findings highlight that the antimicrobial mechanism of H_2O_2 is not governed solely by its concentration, but is also influenced by its physical state, exposure conditions, and interaction with specific cellular targets. Nevertheless, because whole microorganisms are exposed during bio-decontamination, multiple direct and indirect mechanisms may occur simultaneously, making it difficult to attribute microbial death to a single molecular pathway [18,20].

Microbial inactivation should also be understood as a surface-dependent process. The effectiveness of H₂O₂ is influenced not only by the bulk concentration measured within the enclosure, but also by the conditions at the treated surface, including temperature, humidity (especially for vaporized hydrogen peroxide), surface characteristics, and local availability of the active agent. Studies have demonstrated that carrier-surface properties such as hydrophobicity can influence spore inactivation under vaporized H₂O₂ conditions, reinforcing the importance of considering the actual materials and surface configurations present during cycle development and validation [33].

4.4 D-value, Log Reduction, and the Rationale for Biological Indicators

The D-value is defined as the exposure time, under defined process conditions, required to achieve a one-log (90%) reduction in a population of a specific test organism. It is a fundamental kinetic parameter used to characterize the resistance of a biological indicator (BI) and to assess the lethality of a decontamination process. In simple terms, each additional D-value corresponds to another 90% reduction in the surviving population.

For surface bio-decontamination of isolators and barrier systems, a minimum 6-log reduction of a highly resistant bacterial spore population is commonly used as a validation target. The BI is selected with a defined population and characterized D-value to demonstrate that the validated cycle can achieve the required reduction with an appropriate safety margin. The D-value is meaningful only under the defined reference conditions under which it was determined. Depending on the application and risk assessment, this may involve an overkill or half-cycle/full-cycle approach, analogous to concepts used in terminal sterilization validation. Importantly, the log reduction is the performance outcome, while parameters such as hydrogen peroxide concentration, relative humidity (RH), temperature, and exposure time are the process variables used to reliably achieve that outcome at the defined worst-case locations.

A BI with a known population and characterized D-value provides direct, organism-based evidence that the required microbial reduction was achieved at the specific location where the BI was placed and under the actual conditions of the cycle. This complements indirect measurements such as chemical indicators and process sensor data, which demonstrate process conditions but do not directly demonstrate microbial inactivation. For hydrogen peroxide bio-decontamination, the commonly used test organism is the bacterial endospore *Geobacillus stearothermophilus*, with BIs typically traceable to strains such as ATCC 7953 or ATCC 12980 [13].

However, BIs also have inherent limitations. Because they are biological products, spore enumeration can vary considerably, reported at approximately -50% to +300% [12]. Consequently, the actual spore population may differ substantially from the nominal population stated for the BI. BIs also require incubation before the result can be determined, which can slow cycle development and validation. Conventional BIs generally provide a qualitative pass/fail outcome, rather than directly quantifying the achieved log reduction.

Another atypical result may arise from a “rogue” BI, where spores survive a cycle under conditions that would normally be expected to achieve inactivation. Such apparent false positives may be associated with factors including spore agglomeration, accumulation or coalescence near the edge of the carrier, protective or catalytic substances within carrier debris, or spores lodged in scratches or surface defects. These phenomena can create localized protection from limited penetration capability of hydrogen peroxide [13]. A suspected anomalous BI result should never be dismissed as a rogue BI without documented investigation and supporting evidence.

5. Bio-decontamination Technologies Around Hydrogen Peroxide

5.1 Vaporized Hydrogen Peroxide (VHP)

Vapor-phase hydrogen peroxide (VHP) is a bio-decontamination process in which hydrogen peroxide is introduced into the chamber as a gas/vapor and distributed throughout the enclosure. In conventional VHP operation, the chamber is actively dehumidified before hydrogen peroxide injection to control the water vapor content and minimize macroscopic condensation. The objective is to maintain hydrogen peroxide predominantly in the gas phase rather than forming a visible liquid film on surfaces.

The fundamental mechanism involves gas-phase transport, surface adsorption, and subsequent oxidative inactivation of microorganisms. However, describing VHP simply as a completely “dry” process can be misleading. At the microscopic level, adsorption and thin-film formation can occur, and microcondensation may contribute to the overall inactivation mechanism even when no visible liquid condensation is present [14, 17].

VHP Principle



Figure 5. VHP Illustration. Courtesy of Esco.

A typical VHP cycle consists of four main phases:

Preparation / Dehumidification (Phase I)

The chamber is conditioned by reducing the relative humidity (RH), typically to approximately 10–20%, depending on the validated cycle. Chamber temperature may also be adjusted to the desired operating condition.

Conditioning (Phase II)

Hydrogen peroxide solution is then transferred from the reservoir to a vaporizer, where it is heated and evaporated, with vaporizer temperatures commonly $\geq 110^{\circ}\text{C}$ depending on the generator design. Vaporized hydrogen peroxide, together with the water vapor originating from the hydrogen peroxide solution, is continuously introduced into the chamber. The hydrogen peroxide concentration gradually increases until the required concentration is reached (e.g. a minimum of 400 ppm). During this phase, distribution throughout the chamber and interaction with exposed surfaces are established.

Decontamination (Phase III)

Once the target hydrogen peroxide concentration is achieved, the concentration is maintained for the required exposure period. The combination of hydrogen peroxide concentration, exposure time, temperature, humidity, and surface conditions determines the microbial inactivation achieved during this phase.

Aeration (Phase IV)

Following the exposure period, hydrogen peroxide is removed from the chamber, typically by introducing fresh air and/or using an exhaust and catalytic destruction system. Aeration is often one of the longest parts of the cycle and continues until the hydrogen peroxide concentration reaches the defined safe level for personnel and/or the product and process, for example ≤ 1 ppm, or a lower validated limit where required.




Figure 6. The hydrogen peroxide concentration over time in VHP cycle

Factors Influencing VHP Effectiveness

The relationship between hydrogen peroxide concentration and humidity is particularly important. Increasing hydrogen peroxide concentration generally increases the rate of microbial inactivation, while humidity can also influence the kinetics of the process. At lower hydrogen peroxide concentrations, achieving the same microbial reduction may require higher humidity [14]. However, increasing humidity also increases the likelihood of condensation, which can extend aeration time and increase the risk of material degradation or corrosion [15].

Importantly, the absence of visible condensation does not necessarily mean that no surface liquid phase exists at the microscopic level. Surface deposition can occur progressively through adsorption of gas molecules, formation of a thin aqueous film, and subsequent growth into larger droplets. The formation of microscopic deposits of aqueous hydrogen peroxide on surfaces is commonly described as microcondensation [14].

This distinction is important because some literature and industry discussions divide VHP into “dry-VHP” and “wet-VHP”, using the presence or absence of condensation as the differentiating factor. In reality, the boundary is not always physically absolute. Under conditions commonly encountered in pharmaceutical isolators, such as approximately 20% RH and 25–30°C, some degree of microscopic condensation can occur when hydrogen peroxide vapor and water vapor are introduced into the chamber [16,17]. Experimental observations have also reported microcondensation across the tested combinations of humidity and hydrogen peroxide concentration, demonstrating that microscopic deposition cannot necessarily be eliminated simply by operating below the visible dew point [15].

Therefore, VHP should not be understood as a process in which condensation is inherently absent. The more meaningful distinction is between controlled vapor-phase operation with no undesirable macroscopic condensation or liquid pooling, and processes intentionally operated with substantial surface condensation. A certain degree of microscopic surface deposition may occur naturally and may even contribute to rapid microbial inactivation.

Advantages and Limitations

VHP is widely applied to isolators, RABS, pass-through chambers, and other enclosed pharmaceutical and life-science systems. Its major advantages include relatively rapid aeration when excessive liquid condensation is avoided and effective gas-phase distribution into small gaps and complex geometries. In system designs where hydrogen peroxide vapor is intentionally circulated through the supply HEPA/ULPA filter, the process can also contribute to in situ decontamination of the filter, provided this capability is demonstrated and validated as part of the cycle. Furthermore, VHP is a well-established bio-decontamination technology with extensive industry experience and regulatory familiarity. Its explicit mention in the FDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice (2004) further demonstrates its established regulatory recognition and may provide greater confidence when selecting the technology.

However, VHP systems typically require more sophisticated control of humidity, temperature, injection, concentration, and aeration, which can increase system complexity and cost. Cycle performance may also be sensitive to humidity excursions, surface characteristics, and temperature distribution. For large or geometrically complex chambers, achieving uniform hydrogen peroxide distribution may require careful generator quantity and configuration, injection-point selection, airflow management, and potentially CFD-supported design. Ultimately, successful validation of a vaporized hydrogen peroxide (VHP) bio-decontamination process should not be judged solely by whether a particular hydrogen peroxide concentration or exposure level has been reached. The effectiveness of the process must be demonstrated through a holistic assessment of the validated cycle, including its ability to consistently achieve the required microbial reduction at defined and appropriately justified worst-case locations. VHP may be particularly advantageous in applications where the facility infrastructure, equipment design, and operating procedures have already been established around VHP-based bio-decontamination. In such cases, existing generators, distribution arrangements, monitoring practices, safety controls, and standard operating procedures may provide an established framework for implementation and validation. This can reduce the need for significant changes to the facility or operating model when introducing or maintaining the bio-decontamination process.

VHP may also be considered where the customer or end user places value on a technology with extensive historical application in pharmaceutical manufacturing, particularly for isolators and other closed barrier systems. Familiarity with this technology can support the development of established validation approaches, operator procedures, maintenance practices, and regulatory documentation. However, prior industry use should not replace application-specific qualification.

5.2 Atomized Hydrogen Peroxide (AHP)

In this paper, AHP refers specifically to aerosolized H_2O_2 generated through mechanical or pneumatic atomization, terminology varies across suppliers and literature. Unlike true vapor-phase hydrogen peroxide (VHP), where hydrogen peroxide is converted into the gas phase through evaporation or vaporization, AHP introduces the biodecontaminating agent primarily as liquid droplets suspended in air. The droplets are designed to remain airborne long enough to distribute throughout the chamber before depositing onto exposed surfaces. The resulting decontamination performance is therefore governed not only by hydrogen peroxide concentration and exposure time, but also by droplet size distribution, aerosol transport, evaporation, deposition, surface coverage, and condensation behavior.

AHP Principle




Figure 7. AHP Illustration. Courtesy of Esco.

A typical AHP cycle consists of three main phases:

Priming (Phase I)

Hydrogen peroxide solution is transferred from the reservoir to the atomizer nozzle. The system establishes a stable liquid supply and prepares the atomizer for injection.

Atomization, Injection and Dwell (Phase II)

Hydrogen peroxide is atomized, typically using pressurized compressed air, to generate fine droplets that are distributed throughout the chamber. The aerosol is transported by the chamber airflow and gradually deposits onto exposed surfaces. Depending on the system and validated cycle, multiple injection stages with intermediate dwell periods may be used to increase surface exposure and improve distribution.

Aeration (Phase III)

After the required injection and dwell period, hydrogen peroxide is removed from the chamber using fresh-air supply and/or exhaust until the concentration reaches the defined operational limit. As with VHP, the required aeration endpoint depends on the application, product, and personnel exposure requirements.

Factor Influencing AHP

A critical variable in AHP is droplet physics. Droplet size directly influences suspension time, transport, deposition, and surface coverage. Smaller droplets generally remain airborne for longer and can improve distribution throughout large or complex spaces, while larger droplets have a greater tendency to coalesce and settle under gravity. Excessive deposition can result in localized wetting, condensation, or even dripping, potentially creating non-uniform exposure and extending the aeration phase.

Application and Limitations

One of the main advantages of AHP is its ability to distribute hydrogen peroxide solutions without requiring the same degree of pre-conditioning associated with conventional vapor-phase processes. Because the bio-decontaminating agent is introduced as an aerosol rather than relying exclusively on vapor-phase transport, the process can be less dependent on maintaining a narrow temperature and humidity window during injection.

The direct deposition of hydrogen peroxide droplets onto surfaces can also provide effective surface coverage across complex chamber geometries. This makes AHP particularly attractive for large isolator, material airlocks, room-scale bio-decontamination, and applications where broad surface coverage is prioritized.

The principal limitation of AHP is the potential for excessive surface deposition and condensation. If droplets are too large, injection rates are excessive, or the chamber conditions promote coalescence, hydrogen peroxide can accumulate as a liquid film or droplets on surfaces. This can increase aeration time, create material-compatibility concerns, and potentially result in non-uniform distribution. Consequently, AHP performance is highly dependent on atomizer design, compressed dry air supply, droplet size distribution, injection rate, airflow pattern, chamber geometry, and surface characteristics.

5.3 Nebulized Hydrogen Peroxide (NHP)

Nebulized hydrogen peroxide (NHP) is another approach to delivering hydrogen peroxide as a fine aerosol for enclosed-space bio-decontamination. In practice, the terms nebulized, atomized, and aerosolized hydrogen peroxide are sometimes used interchangeably, which can create confusion when comparing different technologies. From a physical perspective, aerosol is the broader term describing liquid droplets suspended in a gas, while atomization and nebulization describe different approaches used to generate those droplets.

Therefore, the key distinction should not simply be whether a system produces an aerosol (both atomized and nebulized systems do), but rather how the aerosol is generated and what droplet characteristics are produced. Conventional pneumatic or mechanical atomization generally uses pressure, air shear, or mechanical forces to break the liquid into droplets. In contrast, the nebulization technology considered here uses a piezoelectric micro-

perforated mesh, in which ultrasonic vibration drives the liquid through microscopic openings to generate a finely controlled aerosol. This is a cold atomization/nebulization process, requiring neither compressed air nor intentional heating of the hydrogen peroxide solution.

Principle

The piezoelectric nebulizer operates by converting electrical energy into high-frequency mechanical vibration of a perforated mesh. Hydrogen peroxide solution is supplied to the vibrating mesh, and the oscillation forces the liquid through the microscopic apertures, generating a fine aerosol of droplets.

Unlike thermal vaporization, the process does not require the hydrogen peroxide to undergo a phase change into the gas phase. Similarly, unlike pneumatic atomization, droplet generation does not depend on high-pressured compressed air to break up the liquid. The resulting aerosol can provide a comparatively controlled droplet-generation mechanism, subject to the characteristics of the formulation and operating conditions. Once generated, the droplets are transported through the enclosed volume by airflow and aerosol dispersion. Their ability to remain suspended allows the hydrogen peroxide aerosol to reach surfaces that may be difficult to access through conventional manual application. The bio-decontamination outcome is consequently determined by the combination of droplet generation, aerosol transport, deposition, surface coverage, hydrogen peroxide concentration, exposure time, and subsequent aeration.

Factors Affecting Performance

The most important parameters for nebulized H_2O_2 are related to aerosol physics. Droplet size has a direct influence on aerosol residence time, transport, deposition, and surface coverage. Smaller droplets generally remain suspended for longer and can be transported more readily by the chamber airflow, potentially improving distribution throughout complex geometries. Larger droplets, in contrast, have greater gravitational settling and may deposit rapidly near the injection region, potentially creating non-uniform coverage.

The droplet size distribution, rather than simply the nominal or average droplet size, is therefore an important consideration. The generation rate, aerosol concentration, airflow pattern, chamber volume and geometry, temperature, RH, and surface characteristics can also influence the final distribution and deposition behavior. If droplets evaporate significantly during transport, the resulting hydrogen peroxide concentration at the surface may differ from the initial aerosol concentration. Conversely, excessive deposition may lead to surface wetting or condensation, which can increase aeration time and potentially affect material compatibility.

This is also where nebulized H_2O_2 differs conceptually from VHP. VHP relies predominantly on gas-phase transport and surface interaction, whereas nebulized H_2O_2 deliberately introduces hydrogen peroxide as a liquid aerosol. Consequently, the process should be evaluated not only through chamber concentration but also through the ability to generate and distribute the aerosol consistently across defined worst-case locations.

Applications

Nebulized hydrogen peroxide (NHP) can be considered for the bio-decontamination of isolators, enclosed equipment, material transfer areas, pass-through chambers, and other closed or semi-closed volumes where effective distribution of the bio-decontamination agent throughout the treatment space is required. The technology uses a piezoelectric atomization mechanism to generate a fine aerosol from hydrogen peroxide. Depending on the atomizer and nozzle configuration, the resulting droplets may typically be in the micrometer range, e.g. VMD 5 or 8 μm , supporting dispersion throughout the enclosure when combined with an appropriately designed airflow and distribution strategy. Unlike systems that rely on compressed-air atomization or thermal vaporization, piezoelectric nebulization generates the aerosol through mechanical vibration of the liquid. This can provide a relatively compact and controlled agent-generation mechanism and may simplify integration where the equipment and process design are suited to this approach.

The performance of NHP, however, is not determined by droplet size alone. Once generated, the aerosol must be transported and distributed effectively throughout the treatment volume, and the interaction between the nebulizer output and the enclosure airflow becomes an important part of system design. This is particularly relevant for larger or geometrically complex systems, where equipment configuration, internal obstructions, airflow velocity and direction, injection location, nebulizer quantity, aerosol residence time, and potential deposition on surfaces can influence the overall distribution. Consequently, the location and number of nebulizers, injection direction, airflow configuration, and operating sequence should be established as part of the application-specific development and validation process rather than assumed to be transferable between different systems.

Cycle duration can also be an important consideration when evaluating NHP. In some applications, trials may demonstrate shorter overall cycles compared with other hydrogen peroxide-based approaches. A fine aerosol can support rapid distribution of the active agent, while the absence of a thermal vaporization step may provide

a different process profile. In addition, the quantity of hydrogen peroxide introduced into the enclosure and the subsequent removal or decomposition of residual peroxide can influence the required aeration period. However, a shorter cycle should not be attributed solely to smaller droplet size or lower agent consumption. The achievable cycle time is ultimately determined by the complete process, including the required microbial efficacy, agent concentration and exposure, distribution, surface interaction, aeration capability, enclosure volume, load configuration, material compatibility, and residual hydrogen peroxide acceptance criteria. Therefore, any claimed cycle-time advantage should be demonstrated under defined and representative operating conditions rather than generalized across all applications.

From an application perspective, NHP may be advantageous where rapid cycle completion and short turnaround times are operational priorities, particularly when the system can be designed to achieve effective agent distribution with an appropriately controlled nebulization and airflow strategy. It may also be considered where a relatively compact and flexible agent-generation approach is desirable and where the resulting process can be integrated into existing decontamination, monitoring, aeration, and validation workflows.

Limitations

The principal limitation is that nebulized H₂O₂ remains fundamentally an aerosol-based liquid delivery process. The aerosol must be transported through the chamber and subsequently deposit onto the target surfaces. Consequently, poor airflow distribution, inappropriate droplet size, excessive settling, or insufficient aerosol residence time can result in non-uniform surface exposure.

As with other aerosolized H₂O₂ technologies, excessive liquid deposition can also result in condensation, longer aeration times, and potential material-compatibility concerns. The technology therefore requires careful optimization of droplet size, aerosol generation rate, airflow, and exposure conditions.

Importantly, the use of a piezoelectric nebulizer does not automatically guarantee uniform bio-decontamination simply because the generated droplets are small. The critical performance question remains whether the aerosol can be reproducibly distributed and deposited at the worst-case locations while achieving the required microbial log reduction.

5.4 Comparative Summary

Parameter	Vaporized H ₂ O ₂ (VHP)	Atomized H ₂ O ₂ (AHP)	Nebulized H ₂ O ₂ (NHP)
Agent delivery	Primarily vapor/gas phase	Liquid aerosol/droplets	Fine liquid aerosol/droplets
Generation principle	Thermal vaporization of H ₂ O ₂ solution	Mechanical or pneumatic atomization	Piezoelectric micro-perforated mesh
Compressed air	May be used depending on system design	Commonly used for pneumatic atomization	Not required for piezoelectric generation
Heating of H ₂ O ₂	Required for vaporization	Not required	Not required
Conditioning sensitivity	Higher	Application-dependent	Application-dependent
Primary transport mechanism	Gas-phase distribution	Aerosol transport and surface deposition	Aerosol transport and surface deposition
Key physical variable	H ₂ O ₂ concentration, RH, temperature, RS, airflow	Droplet size distribution, injection rate, airflow	Droplet size distribution, injection rate, airflow
Typical process consideration	Dehumidification → conditioning → decontamination → aeration	Priming → atomization/injection → dwell → aeration	Priming → Nebulization/injection → dwell → aeration
Droplet distribution	N/A	Critical	Critical
Material sorption	Important	Important	Important
Airflow dependent	High	High	High
Condensation/deposition	Macroscopic condensation should generally be controlled; microscopic deposition may occur	Higher potential for liquid deposition/ condensation if droplet size or injection is not controlled	Excessive deposition can also lead to wetting/condensation

System complexity	Generally higher control requirements for RH, temperature, concentration and aeration	Relatively straightforward aerosol-generation approach, but dependent on atomizer and compressed-air system	Compact generation mechanism; no compressed air or heating required
Industry/regulatory familiarity	Extensive pharmaceutical industry experience	Established aerosol-based approach; application dependent	Comparatively newer approach; application-specific evidence is particularly important
Potential advantage	Established technology, gas-phase penetration/distribution, regulatory familiarity	Broad aerosol distribution and surface coverage	Fine aerosol generation, flexible integration, potentially shorter cycle in suitable applications
Key limitation	More demanding control of humidity, temperature and condensation	Risk of excessive deposition, wetting and longer aeration	Performance strongly dependent on aerosol physics and airflow; small droplets do not automatically guarantee uniform decontamination

AHP, VHP, and NHP should be viewed as different approaches to delivering hydrogen peroxide into an enclosed environment rather than as directly interchangeable technologies. VHP introduces hydrogen peroxide predominantly in the vapor phase and therefore relies primarily on gas-phase transport, with humidity, temperature, concentration, and condensation behavior playing important roles in process development. AHP and NHP, in contrast, introduce hydrogen peroxide as an aerosol, making droplet size distribution, aerosol transport, deposition, surface coverage, and airflow important determinants of performance.

The principal distinction between AHP and NHP is the method used to generate the aerosol. AHP may use mechanical or pneumatic atomization, with compressed air commonly used to break the liquid into droplets. NHP, as described in this paper, uses a piezoelectric micro-perforated mesh to generate a fine aerosol through high-frequency mechanical vibration, without compressed air or intentional heating of the hydrogen peroxide solution. This difference can influence the generation mechanism, equipment integration, droplet characteristics, and process control strategy, although the resulting bio-decontamination performance remains dependent on the complete system rather than on the generation mechanism alone.

From an application perspective, VHP may be particularly suitable where established VHP infrastructure, operating procedures, and validation strategies already exist, or where the extensive industry experience associated with the technology is an important consideration. AHP may be attractive for applications where broad aerosol distribution and direct surface coverage are prioritized, including larger or relatively open volumes. NHP may offer advantages where a compact aerosol-generation mechanism, flexible integration, and rapid turnaround are important, provided that the aerosol can be consistently distributed throughout the enclosure and adequate surface exposure can be demonstrated.

Importantly, no single technology should be selected solely on the basis of nominal hydrogen peroxide concentration, droplet size, cycle time, or generation mechanism. The appropriate technology depends on the specific enclosure, geometry, airflow configuration, materials, load, required microbial reduction, aeration capability, and operational requirements. For all three approaches, successful validation ultimately requires demonstration of reproducible microbial efficacy at appropriately justified worst-case locations while maintaining acceptable material compatibility, process duration, and residual hydrogen peroxide levels. In this respect, the comparison should be used to identify the most appropriate process-development strategy for a particular application rather than to establish a universal hierarchy among the technologies.

6. Developing a Decontamination Cycle


Development of a hydrogen peroxide bio-decontamination cycle should be treated as a systematic process of establishing the relationship between H₂O₂ delivery, environmental conditions, exposure, and microbial inactivation. Although atomized, nebulized, and vaporized H₂O₂ systems all rely on hydrogen peroxide as the active biocidal agent, each delivery technology creates a different distribution and mass-transfer behavior within the enclosure. Consequently, the critical cycle parameters and their acceptable operating ranges should be established specifically for the technology and equipment configuration being evaluated. A well-developed cycle should demonstrate that the required microbiological performance can be achieved consistently throughout the defined chamber, including difficult-to-reach locations and representative worst-case surfaces, while also maintaining acceptable material compatibility and avoiding undesirable condensation or excessive H₂O₂ residues. Cycle development therefore

generally progresses from an initial characterization of the enclosure and H₂O₂ delivery system, through parameter screening and optimization, followed by microbiological confirmation and robustness assessment.

6.1 The Typical Cycle Structure

A typical H₂O₂ bio-decontamination cycle consists of several sequential phases, commonly described as leak test, preparation, H₂O₂ delivery, exposure and contact, and aeration. The exact terminology and control strategy may vary depending on whether the system uses atomized, nebulized, or vaporized H₂O₂.

► Figure 8. Common Cycle Structure



6.2 How Parameters Interact

The parameters involved in H₂O₂ bio-decontamination should not be considered independently because changes in one parameter can alter the effect of several others. H₂O₂ concentration, exposure time, temperature, relative humidity (RH), relative saturation (RS), airflow, and delivery rate are interdependent variables that collectively influence microbial lethality, agent distribution, and the physical state of the process. For example, increasing H₂O₂ loading may increase the available biocidal agent and reduce the exposure time required to achieve a given microbial reduction; however, increasing the amount of H₂O₂ introduced into the enclosure can also move the process closer to its saturation limit and increase the potential for condensation. Similarly, temperature affects both the kinetics of microbial inactivation and the amount of water and H₂O₂ vapor that can be accommodated by the environment before saturation is reached. Relative humidity is therefore only one part of the environmental picture. In VHP applications, the simultaneous presence of water vapor and H₂O₂ vapor means that the condensation behavior of the system cannot be reliably evaluated from RH alone. Relative saturation provides a more representative indication of how close the combined vapor mixture is to the saturation condition at which condensation may occur.

INTERDEPENDENT VARIABLES IN H₂O₂ BIO-DECONTAMINATION




Figure 9. Interdependent Variables in H₂O₂ Bio-decontamination

This relationship is particularly important during VHP cycle development. As H_2O_2 vapor is introduced into a conditioned enclosure, both H_2O_2 and the water originating from the H_2O_2 solution contribute to the overall vapor loading. At a given temperature, increasing either component reduces the remaining capacity of the environment to accommodate additional vapor. Consequently, a cycle may have an apparently acceptable RH while simultaneously approaching a much higher RS because of the presence of H_2O_2 vapor. When the combined vapor mixture approaches 100% RS, condensation can begin even though RH has not reached 100%. Once condensation occurs, additional H_2O_2 may no longer increase the vapor-phase concentration as expected, and condensed peroxide may remain on surfaces and subsequently contribute to longer aeration requirements.

The relationship between temperature, H_2O_2 concentration, RH, and RS therefore creates an important operating window for VHP. Lowering the initial humidity generally provides greater capacity for subsequent introduction of H_2O_2 vapor before the saturation condition is reached. Increasing temperature can also increase the amount of water and H_2O_2 vapor that the environment can accommodate before condensation. However, these relationships should not be interpreted as a requirement to maximize temperature or minimize humidity independently. The selected conditions must remain compatible with the enclosure, materials, equipment, microbiological efficacy, and validated process strategy. The objective is to establish a sufficiently robust operating window in which the required H_2O_2 exposure can be achieved without undesirable macroscopic condensation or loss of process control.

For VHP, RS can therefore be considered a useful process-development parameter for assessing proximity to condensation/saturation under defined VHP conditions alongside H_2O_2 concentration, temperature, and RH. A cycle operating too close to the saturation boundary may have limited margin against variations in initial humidity, temperature distribution, H_2O_2 delivery, sensor accuracy, or chamber loading. Conversely, operating substantially below the saturation boundary may provide greater protection against condensation but could require changes in H_2O_2 concentration, exposure time, or other process parameters to maintain the required microbial efficacy. The appropriate relationship between these parameters should consequently be established experimentally during cycle development rather than assumed from a single nominal concentration or humidity set point. The concept of RS has been proposed specifically as a means of objectively characterizing how close a VHP process is to the saturation condition during bio-decontamination.

For atomized and nebulized systems, the interaction between process parameters takes a somewhat different form. Because H_2O_2 is introduced primarily as an aerosol rather than as a vapor, droplet size distribution, aerosol generation rate, airflow, residence time, deposition, and surface coverage become particularly important. Smaller droplets may remain suspended for longer and can be transported more effectively by the chamber airflow, whereas larger droplets have a greater tendency to settle and accumulate near the injection region. Increasing the delivery rate may shorten the injection phase but can simultaneously increase local aerosol concentration and surface deposition. Excessive deposition may result in wetting or condensation and subsequently increase aeration requirements. Therefore, although RS is particularly relevant to understanding vapor-phase saturation in VHP, the broader principle of controlling the physical state and distribution of the H_2O_2 remains important for AHP and NHP as well.

The interaction between these variables means that cycle development should focus on identifying a stable operating window rather than a single optimal set point. A useful approach is to initially characterize the system using chemical and physical measurements, such as H_2O_2 concentration, temperature, RH, RS where applicable, and spatial distribution, and then correlate these results with microbiological performance. The development process can then evaluate which parameters have the greatest influence on the response and whether significant interactions exist between them. For example, a condition that performs well at one humidity may not provide equivalent performance at another humidity when the same H_2O_2 concentration and exposure time are maintained. Likewise, increasing the injection rate may shorten the conditioning or injection phase but could create greater local accumulation in an atomized or nebulized system. These interactions become particularly important when moving from a small development enclosure to the final equipment because chamber geometry, internal components, airflow paths, material loading, and surface characteristics can all alter the relationship between process parameters and microbial efficacy.

For this reason, the final cycle should ideally be defined by a combination of process parameters and performance indicators rather than by exposure time alone. Depending on the technology, these may include H_2O_2 concentration, temperature, RH, RS, injection or generation rate, exposure duration, airflow conditions, and aeration performance, together with appropriate chemical, physical, and microbiological indicators. The selected operating ranges should provide sufficient margin to accommodate normal variation in H_2O_2 delivery, environmental conditions, sensor measurement, equipment loading, and chamber configuration while maintaining the required microbiological performance. In VHP applications in particular, maintaining an appropriate margin from the saturation boundary can provide an additional element of process robustness by reducing the sensitivity of the cycle to variations that could otherwise promote undesirable condensation. The final acceptance criteria and operating ranges should, however, remain application-specific and be supported by development and validation data.

6.3 Worst-Case Development

Worst-case development is essential because successful bio-decontamination of easily accessible surfaces does not necessarily demonstrate that the entire enclosure can be reliably decontaminated. The objective is to identify locations, materials, configurations, and operating conditions that present the greatest challenge to H₂O₂ distribution or microbial inactivation. Worst-case locations may include areas with limited airflow, shadowed or obstructed surfaces, corners, recessed features, glove interfaces, transfer systems, equipment components, or locations distant from the H₂O₂ injection point. The assessment should also consider the surface material, surface orientation, cleanliness, and potential presence of residues or organic material, since these factors may influence H₂O₂ availability and microbial survival.

The definition of worst case should also be technology-specific. In an atomized or nebulized system, the worst case may be associated with locations where aerosol transport is restricted or where droplet deposition is uneven. Internal geometry, airflow direction, distance from the atomizer, and potential shielding by equipment can therefore have a significant influence on the result. In a vaporized system, worst-case locations may instead be associated with areas where gas-phase concentration is lowest, mixing is inadequate, or condensation behavior differs from the remainder of the chamber. A location that is considered worst case for one delivery technology should therefore not automatically be assumed to represent the worst case for another.

Ultimately, the purpose of worst-case development is to establish a robust and defensible design space in which the decontamination cycle remains effective despite expected variation in the process. The selected cycle should therefore represent a balance between microbiological efficacy, H₂O₂ consumption, cycle duration, material compatibility, condensation control, and aeration requirements. This approach is applicable to all three technologies, but the variables used to define the design space must reflect the underlying delivery mechanism: droplet generation and deposition for atomized systems, aerosol generation and transport for nebulized systems, and vapor-phase concentration, distribution, and condensation control for vaporized systems.

Inner Door




Figure 10. BI and EI example placement

In a typical aseptic isolator system, the following locations and configurations may represent important challenge locations during cycle development, and each should be evaluated in combination with the surface material at that location, since geometry and material together determine local H₂O₂ availability and microbial survival:

1. Dead legs and shadow areas

Locations shielded from direct line-of-sight or airflow from the injection point, for example, the rear face of equipment skirts, spaces between machine frames, the underside of work surfaces, and recesses behind structural columns, may experience delayed or reduced exposure. Hydrogen peroxide concentration in these zones typically reaches target levels later than in well-mixed regions, and condensation may form later and persist longer. Shadow areas therefore frequently determine the minimum exposure hold time and should be prioritized for BI placement.

2. Complex geometry

Equipment fixtures, tubing manifolds, clamps, sensors, and instrumentation introduce narrow gaps, blind holes, threads, and overlapping surfaces that restrict diffusion. Such features can trap air pockets during conditioning, resist wetting during decontamination, and are difficult to clean; they thus combine a physical barrier to H₂O₂ ingress with an elevated residual bioburden risk. This is a particular concern in atomized and nebulized systems, in which droplet or aerosol transport into narrow features may be limited even when the bulk chamber concentration is satisfactory.

3. HEPA filter faces and housings

Filter media are porous, high-surface-area materials that adsorb hydrogen peroxide differently from smooth stainless steel or polycarbonate surfaces, altering local kill kinetics and importantly prolonging aeration and off-gassing after the exposure phase. Filter housings, clamping frames, and downstream ductwork can additionally create low-velocity zones in which condensate accumulates. Filter locations may represent either a decontamination or aeration challenge, depending on filter type, configuration, airflow and process design.

4. Transfer hatches and rapid transfer ports (RTPs)

The mechanical door and seal design of hatches and RTPs creates interfaces such as door gaskets, interlock mechanisms, bellows, and the annular clearance around the door that are geometrically and materially distinct from the general chamber volume. These interfaces can present localized worst-case behavior in both directions: restricted H₂O₂ ingress during exposure and retained residual peroxide during aeration. Each transfer device should be treated as a separate worst-case zone with dedicated indicator placement.

5. Glove sleeves and glove ports

Flexible, low-thermal-mass sleeve materials respond differently to conditioned air than rigid chamber walls, and folds or creases can shield surfaces from direct exposure while simultaneously trapping residual hydrogen peroxide. Glove sleeves may therefore underexpose during decontamination yet remain the last locations to clear during aeration. Glove ports positioned far from the injection point, or located between the nozzle and the air return, are typical worst-case candidates.

Worst-Case Load Versus Full Load and Empty Load

A distinction must also be drawn between the worst case defined by location and the worst case defined by load configuration. The terms empty load, full load, and worst-case load describe different points on the load envelope and are not interchangeable.

The empty load (empty chamber) represents the lower bound of the load envelope: no equipment is present, sorptive and thermal burden is minimal, and chamber conditions equilibrate most rapidly. Empty-chamber runs are valuable for mapping gas-phase concentration, condensation behavior, and aeration kinetics without confounding by the load, but they do not demonstrate efficacy under operating conditions and can be misleading in the opposite direction, in the absence of material to consume hydrogen peroxide, local concentrations may be higher, and condensation control easier, than will ever occur in practice.

The full load represents the upper bound: the maximum intended equipment loading arranged in its normal, orderly configuration. Full-load cycles establish that the cycle can meet total H₂O₂ demand and thermal/moisture burden under routine operation. A high load, however, is not automatically the most challenging load; if items are spaced and oriented to preserve airflow, even a densely filled chamber may present fewer shielded surfaces than a smaller, poorly arranged load.




Figure 11. Example of BI and CI placement in worst-case load

The worst-case load is defined by configuration rather than quantity. It is the loading arrangement that maximizes the challenge to distribution and inactivation, for example, nested or stacked components that shadow one another, tubing racked so that inner surfaces are occluded, items deliberately placed in airflow shadows or between the injection point and the return, or sorptive materials (gaskets, filter media, packaging components) positioned where they delay attainment of target conditions. In practice, a partial but obstructive load is often more demanding than a full, well-arranged one, and the worst-case configuration should be selected on the basis of a documented risk assessment rather than load mass alone.

Configuration	Defining characteristic	What it demonstrates	Principal limitations and remarks
Empty load	No equipment with minimal sorptive burden	Baseline distribution, condensation mapping	No demonstration under operating conditions
Full load	Maximum intended loading in normal arrangement	Routine capability	Orderly arrangement may avoid worst-case shielding
Worst-case load	Configuration maximizing distribution challenge (shadowing, occlusion, sorptive material)	Efficacy at the most difficult configuration	Must be justified by risk assessment

Cycle development should bracket the load envelope by demonstrating, at minimum, the empty and worst-case configurations; the full-load configuration should additionally be qualified where it differs materially from the worst case. For routine operation, the validated states should be bounded by a load configuration specification by defining permitted item types, quantities, orientations, and positions, so that any load falling within the validated envelope remains qualified. Any change to load geometry, equipment layout, or chamber configuration outside this envelope should trigger re-evaluation of the worst-case assessment rather than being assumed to remain within the validated design space.

6.4 Hydrogen Peroxide Desorption and Residue

6.4.1 Sorption During Decontamination as the Origin of Residues


During the decontamination phases, hydrogen peroxide distributes not only in the gas phase for VHP or droplet size in AHP and NHP but also partitions into the materials exposed within the enclosure. Two mechanisms dominate: adsorption on porous or high-surface-area materials such as HEPA filter media, gasket elastomers, and painted or textured surfaces, and absorption into polymers such as glove sleeve materials, Tyvek packaging, polypropylene components, and silicone tubing. The quantity taken up is a function of the material, the hydrogen peroxide concentration, relative humidity, temperature, and exposure duration. Sorption is therefore material-specific, and the load configuration directly influences how much peroxide the enclosure must subsequently release.

The practical consequence is that the sorptive burden of the load frequently determines how much H_2O_2 is available for slow release later. Yabuta et al. quantified the impact of polymer sorption on aeration duration in pharmaceutical decontamination, demonstrating that sorptive materials can extend the aeration phase well beyond the time predicted from chamber purge alone [24]. Similarly, Eisner et al. showed that silicone tubing and primary packaging components act as significant H_2O_2 sinks during isolator decontamination, with uptake varying according to pretreatment and sterilization history [25].

6.4.2 Desorption Kinetics and the Aeration Endpoint

When injection ceases, the hydrogen peroxide concentration falls rapidly by dilution and exhaust, but peroxide that has partitioned into materials returns to the gas phase only as fast as the desorption kinetics allow. The result is a characteristic off-gassing tail: the measured bulk concentration may plateau above the target for an extended period even with continuous aeration, because the chamber atmosphere is being re-supplied from surfaces, filters, gaskets, and polymeric items. Aeration is consequently the longest phase of many H_2O_2 cycles, and its duration is defined by desorption from the worst-case sorptive locations rather than by air exchange alone.

The aeration endpoint must therefore be defined per application, based on risk assessment, and two distinct targets should be recognized. For operator safety, the endpoint is conventionally aligned with occupational exposure limits (1 ppm 8-hour TWA; OSHA PEL). For product protection, however, the tolerable residual may be substantially lower: the aeration target is typically not more than 1 ppm, but can be even lower for products shown to be highly sensitive to oxidation [26]. It should also be recognized that a hydrogen peroxide sensor reading reflects the bulk atmosphere at the probe location; bound residue on surfaces and within materials is not directly visible in that measurement. Endpoint determination should therefore be justified, whether parametric with a conservative aeration hold, or verified periodically by direct low-level measurement at representative surfaces and product-contact components.



► Figure 12. Hydrogen peroxide sorption and desorption

6.4.3 Risk to Product and Process

Residual hydrogen peroxide reaches the product through three principal pathways: (i) diffusion of residual vapor into open or partially filled containers during filling, a mass-transfer process shown to be predictable by mechanistic modeling [27]; (ii) desorption from product-contacting surfaces such as filling needles, pump heads, silicone tubing, and single-use assemblies into the product path during and after aeration [25]; and (iii) transfer of adsorbed residues on containers, stoppers, and packaging introduced through transfer hatches.

For biologics and other oxidation-sensitive products, the risk is well documented. Hydrogen peroxide oxidizes methionine residues to methionine sulfoxide via a two-electron oxygen-transfer reaction; in monoclonal antibodies this reaction is stoichiometric (1:1) and follows pseudo-first-order kinetics, and Hui et al. demonstrated that kinetic modeling of H₂O₂ spiking studies can predict the extent of Fc methionine oxidation (Met 252, Met 428) for a given residual level. This study provides a quantitative basis for defining a product-specific maximum allowable residual [28]. In the presence of transition metals, H₂O₂ also generates hydroxyl radicals capable of oxidizing tryptophan, tyrosine, and histidine, and residual peroxide oxidizes polysorbate surfactants to reactive peroxides and aldehydes that propagate further protein degradation [26]. Oxidation in complementarity-determining regions can reduce binding and potency, while Fc oxidation can reduce FcRn binding and shorten serum half-life.

6.4.4 Risk Management of Residues

Where residual H₂O₂ may pose a product-quality risk, product-specific compatibility or residual-impact studies should be considered based on product sensitivity and risk assessment. A defensible residue control strategy combines the following elements. First, the maximum tolerable residual for each product should be established through H₂O₂ spiking studies linked to critical quality attributes, using the kinetic framework of Hui et al. [28] and reviewed in Meleties et al. [26]. Second, uptake and desorption kinetics should be characterized for the worst-case materials and load configurations, so that aeration is validated to a product-protective endpoint rather than merely to the operator-safety endpoint. Third, mitigation measures may include selection or pretreatment of low-sorption materials (pretreatment of silicone components has been shown to reduce subsequent uptake), directed airflow across known desorption worst cases, and conservative aeration holds with verified margins. Finally, routine control should treat aeration as a validated, parametrically monitored phase with alarm and batch-disposition criteria for incomplete aeration, periodic verification at low level, and inclusion of aeration data in the contamination control strategy documentation.

7. Validation Strategy

Development of a hydrogen peroxide bio-decontamination cycle should be treated as a systematic process. The validation strategy follows the conventional IQ/OQ/PQ framework, which is common to all three delivery technologies. What differs between VHP, AHP, and NHP is not the structure of the qualification but the process variables that must be challenged within each phase: vapor-phase concentration, distribution, and condensation control for VHP; droplet generation and deposition for AHP; and aerosol generation and transport for NHP.

7.1 Qualification Framework (IQ/OQ/PQ)

Installation Qualification (IQ) verifies that the generator, chamber, sensors, and associated utilities are installed correctly and in accordance with specification. This includes confirmation of the calibration status of all critical instrumentation, including hydrogen peroxide sensors, temperature and humidity sensors, pressure and airflow instrumentation, and door/damper position feedback, as well as verification of software versions, utilities (power, process air, drainage), and the as-built configuration of the chamber and airflow paths.

Operational Qualification (OQ) demonstrates that the system operates as intended across its specified operating range, independent of a specific production load. For all technologies this includes empty-chamber distribution studies, sensor verification against independent references, alarm and interlock function testing, and confirmation that each automated phase executes within its validated timing and parameter windows. The distribution studies must use measurements appropriate to the delivery mechanism: gas-phase concentration mapping and condensation margin determination for VHP, deposition coverage mapping (e.g., chemical indicator arrays across multiple surface orientations) for AHP, and aerosol concentration mapping for NHP. Where a chamber is intended to operate with more than one technology or configuration, OQ should cover each claimed operating state.

Performance Qualification (PQ) demonstrates that the cycle, executed with the intended production load or a documented worst-case surrogate load, reliably achieves the required log reduction at all challenge locations across multiple consecutive runs (three consecutive successful runs are commonly used as one element of PQ, although the appropriate number should be scientifically justified), thereby providing the statistical basis for routine reliance on the cycle. PQ acceptance is based primarily on biological indicator results supported by chemical indicators and parametric data and must include the aeration endpoint criteria.

7.1.1 Pre-Cycle Prerequisites, Sequence, and Interlocks

The automated cycle must be preceded by defined prerequisite checks and protected by hard interlocks, the behavior of which should themselves be challenge-tested during OQ. The following represents an example of control/interlock logic for illustration:

Before cycle starts: no hardware/system faults, H2O2 reservoir bottle level is not low or empty, all relevant doors must be closed; The load must be confirmed against the validated load configuration specification, instrumentation must be within calibration, and no active critical alarms may be present.

During the cycle: the system automatically closes the dampers when decontamination starts; bio-decontamination sequence proceeds fully automatically with validated, settable stage timing bounded by the validated ranges. Dampers are open during aeration. Door-request attempts during the cycle are logged and remain blocked. Any deviation from validated parameter windows must alarm and be dispositioned.

After the cycle: doors remain interlocked until hydrogen peroxide has fallen below the defined release limit, and indicator recovery is performed only after the aeration endpoint is confirmed. Cycle records form part of the batch documentation records.

7.2 Cycle Development Within Validation

Cycle development results in a validated cycle recipe. Development should proceed iteratively:

- Distribution mapping runs (using chemical indicators and physical measurements per Table 1) identify low-exposure regions
- Fractional or overkill BI runs at varying exposure establish the failure envelope and the minimum dwell achieving full kill at every worst-case location
- Condensation behavior is characterized by VHP (dew-point margin relative to saturation at chamber surfaces) and drying behavior for AHP and NHP (residual liquid film); and aeration is characterized in terms of desorption tails and endpoint determination.

The outcome is a set of cycle parameters such as conditioning temperature and humidity, injection rate and total delivered quantity, dwell time, and aeration time/endpoint, depending on different bio-decontamination technology opted, each with a validated operating range within which setpoints may be adjusted without triggering re-validation. Development must explicitly cover the load envelope defined in Section 6.3 (empty or worst-case load), and any change to load geometry, chamber configuration, equipment, or parameters outside the validated ranges must be treated as a re-validation trigger.

7.3 Biological Indicators

Geobacillus stearothermophilus spores are the standard BI organism for hydrogen peroxide bio-decontamination, selected for their high and well-characterized resistance to oxidative processes, long history of use and regulatory acceptance, and commercial availability with certified population and D-value, consistent with ISO 11138-1 and -7 and USP <1229.5>.



Figure 13. Observation of BI growth in medium after incubation

- **Population**, the certified number of viable spores per carrier (commonly $\sim 10^6$ for surface bio-decontamination), which together with the target log reduction defines the statistical basis for the efficacy claim at that location.
- **D-value**, the certified time for one log reduction under defined reference conditions; used with population to characterize BI resistance and support lethality calculations.
- **Positive and negative control**, where BIs are used, each test should include appropriate positive and negative controls and the BI system should be operated in accordance with the manufacturer's specified conditions.
- **Placement**, BIs must be placed at every identified worst-case location, oriented to represent the most challenging exposure geometry rather than the most convenient mounting position. Placement must not rely on single "representative" points at convenient monitoring positions, a passing BI at an exit port or well-mixed central location does not guarantee efficacy at peripheral or shielded surfaces, as demonstrated in a HEPA housing decontamination study using nebulized H_2O_2 , in which exit-port BIs passed while BIs at the filter corners failed under marginal exposure [29].
- **Recovery and controls**, post-exposure BI carriers are aseptically recovered and incubated by the manufacturer's validated method; growth (positive) or no-growth (negative) results at each location are the primary PQ acceptance data. Each run must include unexposed positive controls (demonstrating spore viability) and handled negative controls, and the demonstration of the required log reduction (commonly a full kill of a $\geq 10^6$ population BI at all worst-case locations). An important limitation of conventional BIs is that the primary outcome is generally binary: growth or no growth. Although quantitative approaches can provide additional information in specific circumstances, routine BI monitoring alone therefore has limited sensitivity for detecting gradual process drift when no BI failure has yet occurred. This is one reason why appropriately qualified CI, EI, and process parameter monitoring can provide useful complementary information.

7.4 Chemical Indicators

Chemical indicators (CIs) provide a rapid, qualitative means of confirming that a defined chemical exposure condition has been reached at a particular location. In hydrogen peroxide bio-decontamination studies, CIs can therefore be useful during preliminary cycle development to visualize the distribution of the process throughout an isolator or enclosed chamber. However, a CI response does not demonstrate microbial lethality and should not be used as a substitute for biological indicators (BIs) when demonstrating the microbiological efficacy of a validated decontamination cycle.






Figure 14. Observation of Chemical Indicator

For the CI described here, the indicator tape and the indicator bar on the chemical indicator strip undergo a visible color change from blue toward pink following exposure to hydrogen peroxide. The color-change mechanism is based on an oxidation reaction. The blue dye is oxidized by hydrogen peroxide exposure to form a colorless product. The indicator ink also contains a second dye that is not affected by hydrogen peroxide. As the blue dye loses its color, the underlying or remaining dye becomes visually apparent, resulting in a characteristic pink appearance.

The intensity and final shade of the color response may vary depending on the exposure conditions and the characteristics of the indicator. In practical cycle-development studies, the response may therefore range from a relatively weak or partial color change to a more pronounced pink coloration. However, differences in color intensity should not automatically be interpreted as a direct or quantitative measurement of hydrogen peroxide concentration, exposure dose, or microbial inactivation unless such a relationship has been specifically established and validated for the particular CI.



Processed **ACCEPT**



After processing, indicator is color match or acceptable shade of pink. Final end point reaction is confirmed by comparison of sterilized color to color reference match.

Figure 15. Different shades of pink observation due to different exposure to hydrogen peroxide and the acceptable criteria

Despite this limitation, CIs can be particularly useful during the preliminary mapping stage of cycle development. Multiple indicators can be positioned at representative and potentially challenging locations throughout the isolator, including areas with restricted airflow, around equipment interfaces, behind or beneath components, and other locations identified through airflow assessment or risk evaluation. Comparing the visual responses across these locations can provide an initial indication of whether the chemical exposure is being distributed consistently throughout the chamber and can help identify locations that warrant further investigation.

A location showing a weaker or incomplete CI response may indicate that the process conditions at that position differ from those at more readily exposed locations. Such observations can be used to guide subsequent investigation of airflow patterns, H_2O_2 distribution, injection strategy, conditioning, and cycle parameters. The CI therefore functions primarily as a visual process-development tool: it helps identify potential exposure challenges and supports the selection of locations for more rigorous qualification studies, but it does not by itself establish that a location has achieved the required level of decontamination. Final demonstrations of microbiological efficacy should rely on an appropriately designed validation strategy incorporating BIs and other relevant process measurements and acceptance criteria.

7.5 Emerging: Enzymatic Indicators

Enzymatic indicators (EIs) represent an emerging approach to monitoring hydrogen peroxide bio-decontamination by using the inactivation of a defined enzyme system as a surrogate for biological inactivation. A commonly investigated approach uses thermostable adenylate kinase, with the residual enzyme activity determined through a luciferin-luciferase-based assay. The enzyme system is designed and calibrated so that its loss of activity under the process conditions can be related to the lethality demonstrated by conventional biological indicators (BIs). Unlike spore-based BIs, which generally require incubation and recovery before a growth result can be obtained, EI systems can provide a readout within minutes, potentially allowing process performance to be assessed during the same working day [30].

The potential value of EIs comes from their ability to provide more immediate information during decontamination cycle development and troubleshooting. Foundational work published in the PDA Journal of Pharmaceutical Science and Technology demonstrated that enzyme-inactivation profiles could track parallel BI log-kill trends across a

series of vapor-phase hydrogen peroxide cycles in a flexible-film isolator [30]. Subsequent studies have further examined the variability of EI responses and their correlation with BI results, highlighting both the potential of the technology and the factors that need to be controlled when interpreting EI data [31]. More recent PDA Journal literature has also continued to explore the application of EIs in the context of formal cycle validation [32].

Compared with conventional BIs, an important advantage of EIs is therefore speed of feedback. A result that can be generated within minutes rather than after several days of biological incubation can support faster iteration during cycle development, allowing process parameters or challenging locations to be investigated without waiting for BI recovery results. EI measurements can also generate a continuous or numerical response, depending on the system, rather than the predominantly binary growth/no-growth outcome of conventional BI testing. This may provide additional information for understanding process trends and comparing relative exposure conditions across different locations or cycles. Because EIs do not contain viable microorganisms, they may also offer practical advantages during routine studies and requalification by avoiding the intentional introduction and subsequent recovery of viable biological challenge organisms.

However, these advantages should not be interpreted as evidence that EIs are already equivalent to conventional BIs for all applications. The relationship between enzyme inactivation and microbial lethality is process- and system-dependent and must be established for the specific application. At present, EIs remain an evolving technology, and specific regulatory or pharmacopoeial provisions for their use as a direct replacement for conventional BI-based validation are not yet established in the same manner as those for traditional biological indicators. Consequently, the acceptance of EI data should be supported by a documented scientific rationale and an appropriate correlation study against the established BI-based evidence.

The correlation is particularly important because an EI does not respond to the process in exactly the same way as a microbial spore. Factors such as temperature, relative humidity, condensation, hydrogen peroxide concentration, exposure time, surface characteristics, and indicator placement may influence enzyme inactivation independently of, or differently from, microbial inactivation.

EI variability should also be characterized before the technology is relied upon for critical process decisions. Factors such as indicator-to-indicator variability, lot-to-lot consistency, assay repeatability, storage conditions, placement, recovery efficiency, and the sensitivity of the analytical readout can all contribute to variation. The resulting uncertainty should be understood alongside the established variability of the BI method. Where EI data are compared with BI log-reduction data, the correlation should therefore be demonstrated over a representative range of process conditions, rather than relying on a single successful cycle or a single indicator location.

For these reasons, EIs are best positioned today as a complementary tool within the decontamination development and validation strategy. They can provide rapid process feedback, help identify difficult locations, support parameter optimization, and potentially improve understanding of cycle-to-cycle trends. Nevertheless, until sufficient technical and regulatory consensus has been established for a particular application, EI results should not be assumed to independently demonstrate the required microbial lethality or automatically replace BI-based validation. A scientifically justified correlation between EI response and the established BI evidence remains the critical foundation for determining how EI data can be used within a specific decontamination strategy. [16, 30–32]

Indicator	Basis	Readout Time	Demonstrates	Current Regulatory Standing
Biological (BI)	Living spore population	7 days (culture-based)	Direct microbial lethality	Established standard for validation
Chemical (CI)	Chemical reaction to H ₂ O ₂ exposure	Immediate (qualitative)	Threshold exposure reached	Supplemental / distribution mapping
Enzymatic (EI)	Enzyme inactivation kinetics	Minutes	Quantitative enzyme-inactivation response; may be correlated to microbial lethality (log-reduction) where scientifically established	Emerging; supplemental for speeding up BCD

8. Routine Performance Monitoring

Validation establishes the demonstrated state of control; routine monitoring provides ongoing evidence that the validated process continues to operate within its established control strategy. For bio-decontamination systems, this means monitoring not only the microbiological outcome but also the process parameters, equipment condition, load configuration, environmental conditions, and other factors that can influence hydrogen peroxide distribution and efficacy.

Annex 1 places the contamination control strategy (CCS) within a continual lifecycle of review, requiring its effectiveness to be periodically assessed and the CCS to be updated where necessary. Changes to facilities, equipment, processes, materials, and other relevant systems should therefore be evaluated for their potential impact on contamination control before implementation and verified after implementation where appropriate.

For the bio-decontamination system, routine performance monitoring should consequently be designed as a layered control strategy rather than relying on a single indicator. BI data provide direct evidence of biological challenge performance at selected locations; chemical and enzymatic indicators can provide additional process information where appropriately qualified; cycle parameters demonstrate that the validated process conditions were achieved; environmental monitoring provides independent evidence of the broader contamination-control state; and maintenance, calibration, deviation management, and change control protect the reliability of the entire system. The objective is not simply to confirm that individual cycles continue to “pass,” but to identify process drift before it develops into a microbiological failure or loss of validated state.

8.1 Routine Biological Indicator Challenge Frequency

A documented, risk-based strategy should define the frequency and extent of routine BI challenges during production or operational monitoring. The routine approach should be distinguished from the comprehensive BI placement strategy used during performance qualification, where the objective is to characterize the chamber and establish worst-case locations.

The appropriate routine frequency should consider factors such as the criticality of the bio-decontamination process, the demonstrated robustness of the validated cycle, historical BI performance, frequency of production, load variability, equipment configuration, maintenance history, and the potential consequences of an undetected process failure. Where a reduced BI frequency is proposed compared with every-cycle challenge, the rationale should be scientifically documented within the validation and CCS framework and supported by accumulated process knowledge and performance data. Any unexpected BI growth or failure to obtain the expected BI result should be treated as a deviation requiring investigation, rather than being considered simply another routine monitoring result.

8.2 Periodic Requalification

Periodic re-qualification or re-verification should be performed at an established interval based on the site's validation policy and risk assessment and additionally following changes or events that could affect the validated state. The scope of requalification should be determined from the original qualification data, subsequent performance history, equipment changes, maintenance activities, load configuration, and identified worst-case conditions. It does not necessarily need to reproduce every element of the original PQ when a scientifically justified rationale demonstrates that selected worst-case locations and critical conditions remain representative.

The original worst-case map should therefore be treated as a living element of the validation strategy. If subsequent monitoring or change-control activities indicate that airflow, load configuration, material characteristics, condensation behavior, or hydrogen peroxide distribution may have changed, the original worst-case assumptions should be reassessed.

8.3 Cycle Trending

Routine trending of critical and supporting cycle parameters provides an important means of detecting gradual process drift. The parameters selected for trending should be based on the mechanism of hydrogen peroxide delivery and the process variables demonstrated during development and qualification to influence efficacy.

Technology	Parameters that may be considered for routine trending
VHP	Peak hydrogen peroxide concentration; chamber temperature, RS, RH; exposure time; injected quantity; time to reach the ppm setpoint, aeration time and ppm endpoint;
AHP	Delivered/injected rate; aeration time and endpoint; condensation or dripping
NHP	Delivered/injected rate; aeration time and endpoint; condensation or dripping

The exact parameters should not be assumed to be interchangeable between technologies. For example, a gas-phase concentration profile may be an important process measurement for VHP, whereas aerosol-based systems may require greater emphasis on generation, transport, deposition, and drying behavior. A parameter should be included in routine trending when its measurement is reliable and its relationship to process performance has been established during development or qualification.

CI or EI measurements can provide useful supplementary trend information where their response characteristics and limitations are understood. Alert and action limits should be established from the validated process capability, historical performance, measurement uncertainty, and relevant risk assessment, rather than selected as arbitrary percentages around a nominal setpoint.

Particular attention should be given to trends in aeration or clearance time. A gradual increase in the time required to reach the established endpoint may indicate changes in material loading, surface characteristics, sorption behavior, airflow, sensor performance, or bio-decontamination performance. It should therefore be treated as a potential early-warning signal for investigation, even when the formal cycle acceptance criteria continue to be met. Importantly, a trend does not automatically indicate a failure. The purpose of trending is to identify a statistically or operationally meaningful change that warrants assessment before it develops further.

8.4 Alarm Management

Alarm setpoints should have a documented technical rationale, and an appropriate response should be defined for each alarm condition. The alarm strategy should distinguish between alarms that indicate an immediate potential impact on the decontamination cycle and those intended primarily to alert operators to developing equipment or process conditions.

A..No.	Time	Date	Sta...	Description	Acknowledge...
E.. 207	12:08:51	26/02/...	I	Critical : Process chamber total airborne particle counts high (More than 20 particles of $\geq 5.0\mu\text{m}$ size from 1m3 of sampled air)	0
E.. 107	11:58:46	26/02/...	I	Warning: Process chamber high temperature!	0
E.. 307	11:58:16	26/02/...	I	Warning: Pass chamber high temperature!	0
O.. 2016	11:45:27	26/02/...	IO	Warning: H2O2 sterilant low filling level / empty or not loaded properly!	0
O.. 2016	11:43:42	26/02/...	I	Warning: H2O2 sterilant low filling level / empty or not loaded properly!	0
O.. 2112	20:23:13	24/02/...	IO	Warning: Pass chamber biodecontamination cycle aborted!	0
O.. 2112	20:23:08	24/02/...	I	Warning: Pass chamber biodecontamination cycle aborted!	0
O.. 2104	20:15:16	24/02/...	IO	Warning: Master biodecontamination cycle aborted!	0
O.. 2104	20:15:11	24/02/...	I	Warning: Master biodecontamination cycle aborted!	0
E.. 107	20:07:28	24/02/...	IO	Warning: Process chamber high temperature!	0
O.. 2016	19:23:12	24/02/...	IOA	Warning: H2O2 sterilant low filling level / empty or not loaded properly!	0
O.. 2005	19:23:12	24/02/...	IOA	Warning: Process chamber pressure decay test cycle aborted!	0
O.. 2008	19:23:11	24/02/...	IOA	Warning: Pass chamber pressure decay test cycle aborted!	0
O.. 2002	19:23:11	24/02/...	IOA	Warning: Master chamber pressure decay test cycle aborted!	0
O.. 2104	19:23:11	24/02/...	IOA	Warning: Master biodecontamination cycle aborted!	0

► Figure 16. Examples of Alarm Logs

Failure	Potential impact	Automatic abort?	Required response
H ₂ O ₂ sensor failure	Cannot confirm process condition	Yes	Investigate cycle
Door integrity breach	Loss of containment	Yes	Abort/re-establish integrity
RH exceeds setpoint after dehumidification (for VHP only)	Potential efficacy impact	Cycle error, stop sequence	Deviation assessment
Aeration endpoint not reached	Personnel/product risk	No	Continue aeration/investigate
Generation failure	Hydrogen peroxide concentration failed to reach target	Cycle error, stop sequence	Deviation assessment
Dampers not closing	Personnel/environmental risk	Yes	Investigate hardware/software

Alarm performance should also be periodically reviewed. Repeated nuisance alarms may indicate inappropriate setpoints, excessive measurement variability, or deteriorating sensor performance, while the absence of alarms does not necessarily demonstrate that the process remains within its validated state.

Alarms with potential impact on product or process quality should be assessed through the site's established deviation or event-management system. An alarm should therefore not simply be acknowledged and closed without determining whether the event had any impact on the validated process or the affected cycle.

8.5 Environmental Monitoring

Routine environmental monitoring (EM) provides an independent, ongoing assessment of the broader contamination-control strategy. Viable and non-viable monitoring inside or associated with the barrier system can provide useful information about the overall state of environmental control, but EM should not be interpreted as a direct substitute for bio-decontamination validation.

A successful EM result does not demonstrate that every relevant surface or location achieved the required decontamination condition, because EM samples only selected locations and organisms recovered by environmental monitoring may not represent the resistance characteristics of the BI challenge organism.

Conversely, growth in viable air sampler does not automatically demonstrate failure of the bio-decontamination cycle. The growth should be evaluated in the context of the complete contamination-control system, including cycle parameters, BI/CI/EI results where applicable, material transfer practices, cleaning and disinfection, operator activities, and load configuration.

Trending EM data alongside bio-decontamination and process data can nevertheless provide valuable information. For example, recurring recovery at a particular location may prompt investigation of transfer practices, local airflow, surface accessibility, cleaning effectiveness, or changes in the validated configuration.

8.6 Deviation Handling

Bio-decontamination deviations should be investigated using a structured, risk-based approach that considers the entire contamination-control chain rather than assuming that the hydrogen peroxide cycle itself is the root cause.

Potential events include BI growth, incomplete or abnormal CI response, unexpected EI response, failure to achieve the required hydrogen peroxide process condition, abnormal cycle duration, failure to reach the aeration endpoint, sensor alarms, or significant deviation from the validated load configuration.

The investigation should distinguish between:

- process-related causes, such as insufficient exposure, abnormal distribution, generator performance, condensation, or aeration;
- equipment and instrumentation causes, such as sensor drift, calibration failure, airflow changes, or nozzle angle error; and
- upstream or downstream contamination-control causes, such as cleaning, material transfer, or handling practices.

Where a repeated event occurs at the same physical location, simply repeating the same cycle may not provide adequate corrective action. Repeated BI growth or a consistent adverse indicator response should prompt reassessment of the worst-case location, load configuration, hydrogen peroxide distribution, and underlying process assumptions.

CAPA effectiveness should subsequently be demonstrated through objective evidence. Depending on the nature of the event, this may include additional cycle studies, targeted indicator placement, equipment verification, maintenance, revised procedures, or partial/full requalification.

8.7 Change Control

Change control is a critical mechanism for maintaining the validated state because apparently minor modifications can alter hydrogen peroxide distribution or the resistance characteristics of the system. Changes requiring assessment should include, as applicable:

- chamber or isolator modifications;
- HVAC or airflow changes;
- generator, nozzle, or distribution-system modifications;
- changes in gasket, glove, tubing, filter, or other material;
- changes in load quantity, arrangement, or equipment configuration;
- changes in cycle parameters or control strategy;
- changes to sensors or control instrumentation; and
- changes in supplier or material specifications that could affect sorption, condensation, permeability, or surface characteristics.

The assessment should explicitly consider whether the change could affect the established worst-case locations or the validated operating envelope. A change that appears minor from a production perspective, for example, replacement of a gasket material or rearrangement of an internal fixture could alter airflow, hydrogen peroxide accessibility, surface sorption, or condensation behavior and therefore change the location or severity of the worst case. The outcome of the change assessment should determine whether no additional qualification is required, targeted verification is appropriate, or partial/full requalification is necessary.

8.8 Maintenance, Calibration, and Sensor Verification

The reliability of routine bio-decontamination monitoring depends directly on the reliability of the instrumentation used to measure and control the process. A documented maintenance and calibration program should therefore cover, as applicable, hydrogen peroxide sensors, temperature and RH probes, pressure transmitters, airflow measurements, generator instrumentation, and door/damper position feedback.

Calibration status alone may not be sufficient to demonstrate continued fitness for use. Sensor performance should also be assessed through appropriate verification, and diagnostics, particularly for measurements that directly control or determine cycle acceptance.

Hydrogen peroxide measurement systems can be susceptible to drift and may have defined sensor life, environmental limitations, or manufacturer-specific maintenance requirements. Where appropriate, periodic verification against a suitable independent reference or alternative measurement method can provide additional confidence that the process measurement remains representative.

Generator performance should similarly be monitored for gradual deterioration. Depending on the technology, relevant variables may include pump performance, nozzle or atomizer condition, injected weight, airflow, generator output, and other equipment-specific parameters. A growing difference between commanded and delivered conditions may provide an early indication of equipment degradation.

Finally, maintenance activities themselves should be incorporated into the change and deviation assessment process where they could affect the validated state. Replacement of a sensor, pump, nozzle, gasket, glove, filter, or other critical component should not automatically be treated as equivalent to the original component without assessing whether its characteristics could influence process performance.

The objective of maintenance and calibration is therefore not simply to keep instruments within their calibration dates. It is to maintain confidence that the measurements used to control, accept, and trend the bio-decontamination process remain accurate, representative, and fit for their intended purpose.

9. Practical Recommendation

The preceding sections describe bio-decontamination as a lifecycle process: defining the contamination-control requirements, selecting an appropriate hydrogen peroxide delivery technology, developing the cycle, establishing worst-case conditions, demonstrating microbiological efficacy, controlling aeration and residues, and maintaining the validated state through routine monitoring and change control.

For manufacturers, the most important lesson is that these activities should not be treated as independent validation steps performed after equipment selection. The decisions made during enclosure design, technology selection, load definition, cycle development, and routine operation are interconnected. A change in one element can alter the exposure conditions experienced elsewhere in the system. The following recommendations translate this lifecycle approach into practical principles for equipment manufacturers, system integrators, pharmaceutical manufacturers, and validation teams.

9.1 Define the Contamination-Control Requirements Before Selecting the Technology

The bio-decontamination technology should be selected after the application and contamination-control requirements have been defined, rather than selecting a technology first and subsequently determining how to make it work with the enclosure.

The initial assessment should consider, at minimum:

- chamber geometry and internal volume required;
- surface materials and their hydrogen peroxide compatibility;
- internal equipment and obstruction;

- glove and transfer-system configuration;
- load quantity and arrangement;
- expected cycle frequency and throughput;
- temperature and humidity conditions;
- potential condensation and drying requirements;
- aeration requirements;
- required microbiological performance;
- product and material compatibility; and
- the anticipated worst-case locations.

These factors should form part of the contamination-control and process risk assessment and should become explicit inputs to technology selection.

This approach is particularly important because a bio-decontamination system is not simply a hydrogen peroxide generator connected to a chamber. The enclosure, load, airflow, distribution system, generator, sensors, control logic, and aeration system function together as a single process. Selecting equipment primarily on generator capacity, nominal chamber volume, previous site experience, or supplier precedent can therefore create difficulties later during cycle development. A technology that performs well in one enclosure may require substantially different development work in another because the geometry, materials, airflow, or load characteristics are different.

Recommendation: Treat the bio-decontamination system as an integrated process from the beginning of equipment specification, not as an accessory added after the isolator or chamber has already been designed.

9.2 Select VHP, AHP, or NHP According to the Application

There should be no assumption that one hydrogen peroxide delivery technology is inherently the most appropriate for every isolator or chamber.

Vaporized, aerosolized, and nebulized hydrogen peroxide systems differ in how the active agent is generated, transported, distributed, deposited, and removed. These differences can become particularly important in chambers containing complex equipment, restricted airflow paths, porous or sorptive materials, or geometries with limited accessibility.

Technology selection should therefore consider the specific characteristics of the application, including:

- the physical dimensions and geometry of the chamber;
- surface accessibility;
- internal obstructions;
- expected temperature and humidity conditions;
- sensitivity to condensation;
- required cycle duration;
- deposition and drying behavior;
- aeration requirements;

The same physical location may not represent the same challenge across different technologies. A location that is difficult to reach because of gas-phase distribution may not be the same location that presents a challenge for an aerosol or nebulized system, where transport and deposition characteristics become important. Technology selection should therefore be followed by application-specific cycle development rather than assuming that an established cycle from another chamber can simply be transferred.

Recommendation: Select the delivery technology based on the required process mechanism and application-specific risks

9.3 Design and Validate Against the Worst Case

A successful bio-decontamination cycle should demonstrate adequate performance under the most challenging conditions within the intended operating envelope, rather than only under nominal or convenient conditions.

Worst-case assessment should consider both the chamber and the load. Potential challenges include:

- shadowed surfaces;
- dead legs and enclosed geometries;
- areas behind or underneath equipment;
- difficult-to-access surfaces;
- interfaces and penetrations;
- glove and transfer-system components;
- high-surface-area loads;
- materials with greater hydrogen peroxide sorption;
- locations with limited airflow or restricted transport;
- condensation-prone areas; and
- locations that experience slower drying or aeration.

These locations should first be identified through engineering assessment, airflow studies, process knowledge, and risk assessment, and then challenged during qualification using appropriately positioned indicators and process measurements. A successful result at a well-exposed central location should therefore not be interpreted as evidence that the entire chamber has been adequately demonstrated.

Recommendation: Identify the worst case before PQ, deliberately challenge it during qualification, and periodically reassess whether the worst case remains representative after changes to the system or load.

9.4 Treat the Load Configuration as Part of the Validated Process

One of the most frequently overlooked aspects of bio-decontamination validation is the role of the load.

The validated cycle does not apply to an abstract chamber volume. It applies to a defined combination of chamber + equipment + materials + load + configuration + process parameters.

Internal equipment can change airflow, hydrogen peroxide transport, surface accessibility, condensation, and sorption. Even when the total mass or volume of the load remains unchanged, rearranging the components may create new shadowed or poorly exposed locations. The load configuration specification should therefore define the relevant boundaries of the validated state. Depending on the application, this may include maximum and minimum loading, equipment arrangement, orientation, spacing, permitted materials, and other features demonstrated during development and qualification.

Recommendation: Define the permitted load configuration as a controlled process parameter and ensure that routine operation remains within the demonstrated operating envelope.

9.5 Develop the Cycle as a Process, Not a Fixed Recipe

A bio-decontamination cycle should be understood as a sequence of interacting physical phenomena rather than a fixed combination of concentration and time. The critical parameters and their acceptable ranges should be established during development based on their demonstrated relationship with process performance.

For VHP, for example, concentration, temperature, humidity, condensation behavior, exposure time, and aeration can interact strongly. For aerosolized and nebulized systems, generation characteristics, transport, deposition, drying, and subsequent removal may be equally important.

The goal should therefore not be to maximize hydrogen peroxide exposure. Excessive exposure may increase condensation, material interaction, residue, or aeration burden without providing proportional benefit.

Recommendation: Develop the cycle around the mechanism that produces effective and reproducible decontamination while maintaining material compatibility and practical aeration performance.

9.6 Establish the Aeration Endpoint Using All Relevant Acceptance Criteria

Aeration should not be defined solely by how quickly the chamber reaches an occupational exposure limit.

There are potentially several different endpoints:

- personnel or occupational exposure requirements;
- product-contact or material compatibility requirements;
- residual hydrogen peroxide requirements;
- process-specific acceptance criteria; and
- operational requirements for safe opening or transfer.

These criteria should be assessed separately and then combined into a scientifically justified final endpoint.

This distinction becomes particularly important for materials that can absorb or retain hydrogen peroxide and subsequently release it during aeration. A chamber may reach a satisfactory gas-phase concentration relatively quickly while desorption from materials continues to produce a longer residual tail.

For oxidation-sensitive products or materials, the appropriate residual criterion may therefore be more stringent than the criterion established solely for personnel exposure. Where relevant, product or material compatibility should be demonstrated through appropriate studies rather than inferred from chamber concentration alone.

Recommendation: Establish the final aeration endpoint based on the most stringent applicable acceptance criterion, supported by product/material studies and validated measurement methods.

9.7 Use Indicators as Complementary Tools With Clearly Defined Roles

No single indicator provides a complete picture of bio-decontamination performance. A tiered indicator strategy can provide greater process understanding when each technology is assigned a clearly defined role:

Biological indicators as microbiological efficacy

BIs provide evidence of the ability of the process to inactivate a defined biological challenge under the specified conditions. They remain a fundamental component of microbiological qualification where required by the applicable validation strategy.

Chemical indicators as rapid qualitative exposure mapping

CIs provide a convenient visual indication that the indicator experienced a defined chemical exposure response. They can be particularly useful during cycle development for comparing locations and identifying potential exposure challenges.

Enzymatic indicators as rapid process-development feedback

EIs offer the potential for rapid, numerical assessment of enzyme inactivation and can therefore provide useful feedback during cycle development, troubleshooting, and potentially requalification. Their value depends on establishing an appropriate relationship between EI response and the microbiological evidence generated by the established BI approach. EIs should therefore currently be positioned as supplementary process-monitoring or development tools rather than automatically replacing BIs.

Recommendation: Define the intended purpose, limitations, acceptance criteria, and relationship to the validated process for every indicator used.

9.8 Monitor the Process, Not Just the Biological Result

Routine monitoring should extend beyond periodic BI results. A BI result provides important microbiological evidence, but it is generally not sufficient to identify gradual changes before they become failures. Routine monitoring should therefore incorporate appropriate process parameters, equipment status, alarms, environmental information, and indicator data where justified.

Parameters should be trended according to the delivery technology and the variables demonstrated during development to influence process performance. The objective is to identify drift, not merely excursions.

For example, a gradual increase in aeration time may not initially result in a failed cycle, but could indicate changes in material loading, sorption, airflow, generator performance, or instrumentation. Similarly, a gradual change in generator output or sensor response may provide an opportunity for intervention before microbiological performance is compromised.

Recommendation: Trend process data systematically and establish alert/action criteria based on demonstrated process capability and historical performance.

9.9 Treat Instrumentation as Part of the Validation System

The reliability of a bio-decontamination process cannot exceed the reliability of the measurements used to control and accept it. Hydrogen peroxide sensors, temperature/RH probes, pressure sensors, airflow measurements, and generator instrumentation should therefore be managed as critical elements of the control system. Calibration confirms that an instrument has been assessed against a reference under defined conditions. It does not necessarily demonstrate that the sensor remains representative throughout routine operation.

Particular attention should be given to:

- sensor drift;
- sensor aging;
- sensor replacement;
- verification frequency;
- environmental effects;
- independent verification where appropriate;

Sensor health should itself be trended. A drifting H₂O₂ sensor, for example, can create an apparent change in cycle performance even when the underlying process has not changed or can mask a genuine process change.

Recommendation: Combine calibration, verification, maintenance, and sensor-performance trending rather than treating the calibration certificate as the sole evidence of measurement reliability.

9.10 Make Change Control Part of the Bio-decontamination Strategy

The validated state is only meaningful if changes that could affect it are identified and assessed. The assessment should specifically ask:

Could this change alter hydrogen peroxide generation, transport, distribution, deposition, condensation, microbial exposure, or aeration?

If the answer is potentially yes, the change should be evaluated against the established worst-case assessment and validated operating envelope. A change that is operationally minor can nevertheless be significant from a bio-decontamination perspective. Replacing a gasket with a material having different sorption characteristics, for example, may alter aeration behavior even though the chamber volume and cycle recipe remain unchanged.

Recommendation: Evaluate every relevant change against the bio-decontamination mechanism and the established worst-case map, not merely against whether the written cycle parameters have changed.

9.11 Establish a Lifecycle Review Rather Than a One-Time Validation

Establish a periodic review that evaluates whether the assumptions supporting the validated biodecontamination state remain applicable. The review should consider relevant trends, deviations, maintenance and calibration history, change-control assessments, load or material changes, and requalification outcomes. The objective is to determine whether the available evidence continues to support the validated operating envelope and whether additional investigation or qualification is warranted.

9.12 The Manufacturer's Practical Checklist

For practical implementation, the lifecycle can be reduced to ten questions:

Stage	Question to ask
1. Risk assessment	What contamination-control requirement must the bio-decontamination system achieve?
2. Technology selection	Why is this technology appropriate for this specific chamber, material set, and load?
3. Worst case	Where are the most difficult locations and why?
4. Cycle development	Which physical parameters actually drive effective and reproducible exposure?
5. Load definition	What load configuration is included within the validated envelope?
6. Qualification	Has microbiological performance been demonstrated at representative worst-case conditions?

7. Aeration	What is the scientifically justified endpoint, and does it satisfy all applicable criteria?
8. Routine monitoring	Which parameters and indicators can detect process drift before failure?
9. Change control	Could any change relocate the worst case or alter exposure, deposition, or aeration?
10. Lifecycle review	Does current evidence continue to support the validated state?

10. Conclusion

Bio-decontamination of pharmaceutical isolators should no longer be treated as a standalone cycle that is validated once and subsequently operated as a fixed recipe. It is an integral component of the broader Contamination Control Strategy (CCS), and its effectiveness depends on how the process interacts with equipment design, airflow, cleaning and disinfection, material transfer, loading practices, monitoring, and maintenance. A science- and risk-based approach therefore begins by defining the contamination risk and process requirements before selecting the technology or establishing the cycle.

The selection of VHP, AHP, or NHP should be based on the specific application, considering microbial efficacy, chamber geometry, airflow, material compatibility, load configuration, distribution, condensation or deposition, aeration, and operational requirements. Cycle development should focus on establishing a robust operating window rather than a single target concentration or exposure time. The interactions between H₂O₂ concentration, exposure time, temperature, humidity, relative saturation, airflow, delivery rate, and load configuration must be understood and evaluated under appropriately justified worst-case conditions.

Validation should demonstrate that the complete process can consistently achieve the required microbial reduction while maintaining acceptable physical and operational performance. Biological indicators, chemical indicators, and process measurements should be used as complementary tools to demonstrate microbial efficacy, distribution, and control of critical process parameters. Importantly, validation does not represent the end of the process; routine monitoring, cycle trending, instrument calibration, maintenance, periodic review, and requalification are necessary to maintain the validated state throughout the equipment lifecycle.

Ultimately, a robust bio-decontamination strategy is not defined by a particular technology, concentration, or cycle duration, but by the ability to demonstrate that the selected process consistently controls the identified contamination risk and remains capable of doing so throughout its operational lifecycle. The objective is therefore not simply to develop a cycle that works, but to establish a controlled, understood, reproducible, and maintainable process that forms a defensible part of the overall contamination control strategy.

Reference

1. European Commission. *EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Annex 1: Manufacture of Sterile Medicinal Products*. August 2022.
2. *Encyclopedia of Clean Rooms, Bio-Cleanrooms and Aseptic Areas*, Dr. Philip Austin, PE, 2000
3. Mizuno M, Abe K, Kakimoto T. Operator-Derived Particles And Falling Bacteria In Biosafety Cabinets. *Regenerative Therapy*, 2024; 25: 264-272
4. Behrens D, Schaefer J, Keck CM, Runkel FE. Effects of Different Air Change Rates On Cleanroom 'In Operation' Status. *Drug Development and Industrial Pharmacy*, 2021; 47(10), 1643–1655.
5. Whyte W, Hejab M. Particle and Microbial Airborne Dispersion From People. *European Journal of Parenteral and Pharmaceutical Sciences*, 2007; 12 (2). pp. 39-46.
6. Whyte W, Eaton T. Microbial risk assessment in pharmaceutical cleanrooms. *European Journal of Parenteral and Pharmaceutical Sciences*, 2004; 9 (1). pp. 16-23.
7. U.S. Food and Drug Administration (FDA). *Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. Guidance for Industry*. October 2004.
8. DeLeo FR, Allen LA, Apicella M, Nauseef WM. NADPH oxidase activation and assembly during phagocytosis. *J Immunol*. 1999;163:6732–6740.

9. Neyens E, Baeyens J. A review of classic Fenton's peroxidation as an advanced oxidation technique. *J Hazard Mater.* 2003;98:33–50. doi: 10.1016/s0304-3894(02)00282-0.
10. Fridovich I. Biological effects of the superoxide radical. *Arch Biochem Biophys.* 1986;247:1–11. doi: 10.1016/0003-9861(86)90526-6
11. Ikai H, Nakamura K, Shirato M, et al. Photolysis of hydrogen peroxide, an effective disinfection system via hydroxyl radical formation. *Antimicrob Agents Chemother.* 2010;54:5086–5091. doi: 10.1128/AAC.00751-10
12. Schachtschneider, A., Klein, S., & Marshall, K. (2021). Application of enzyme indicators in hydrogen peroxide bio-decontamination cycle development: A critical evaluation of indicator variability and correlation to biological indicator results. *PDA Journal of Pharmaceutical Science and Technology*, 76(1), 34–51. <https://doi.org/10.5731/pdajpst.2020.012294>
13. Sandle, T. (2020) Rogue Biological Indicators: Are They A Real Phenomenon?, *Journal of Validation Technology*, 26 (1): <https://www.ivtnetwork.com/article/rogue-biological-indicators-are-they-real-phenomenon>
14. Unger-Bimczok, B., Kottke, V., Hertel, C., & Rauschnabel, J. (2008). The Influence of Humidity, Hydrogen Peroxide Concentration, and Condensation on the Inactivation of *Geobacillus stearothermophilus* Spores with Hydrogen Peroxide Vapor. *Journal of Pharmaceutical Innovation*, 3(2), 123–133. <https://doi.org/10.1007/s12247-008-9027-1>
15. Hultman C, Hill A, McDonnell G. The physical chemistry of decontamination with gaseous hydrogen peroxide. *Pharm Eng.* 2007;27(1):22–32.
16. Watling D, et al. Theoretical analysis of the condensation of hydrogen peroxide gas and water vapour as used in surface decontamination. *PDA J Pharm Sci Technol* 2002;56(6):291–9. 17.
17. Marcos-Martin MA, et al. Sterilization by vapour condensation. *Pharm Technol Eur* 1996;18(2):24–32.
18. Finnegan M., Linley E., Denyer S.P., McDonnell G., Simons C., Maillard J.-Y. Mode of action of hydrogen peroxide and other oxidizing agents: Differences between liquid and gas forms. *J. Antimicrob. Chemother.* 2010;65:2108–2115. doi: 10.1093/jac/dkq308.
19. McDonnell G. *New Biocides Development*. Volume 967. American Chemical Society; Washington, DC, USA: 2007. Peroxygens and Other Forms of Oxygen: Their Use for Effective Cleaning, Disinfection, and Sterilization; pp. 292–308. (ACS Symposium Series).
20. Linley E. Ph.D. Dissertation. Cardiff University; Cardiff, UK: 2012. Understanding the Interactions of Hydrogen Peroxide with Macromolecules and Microbial Components.
21. Ayub A, Cheong YK, Castro JC, Cumberlege O, Chrysanthou A. Use of Hydrogen Peroxide Vapour for Microbiological Disinfection in Hospital Environments: A Review. *Bioengineering (Basel)*. 2024 Feb 22;11(3):205. doi: 10.3390/bioengineering11030205. PMID: 38534479; PMCID: PMC10967804.
22. Alasri A, Valverde M, Roques C, Michel G, Cabassud C, Aptel P. Sporocidal properties of peracetic acid and hydrogen peroxide, alone and in combination, in comparison with chlorine and formaldehyde for ultrafiltration membrane disinfection. *Can J Microbiol.* 1993 Jan;39(1):52–60. doi: 10.1139/m93-008. PMID: 8439874.
23. Kozmenko V, Gonzales RR Jr, Riopelle J, Kaye AD. Disinfection Agents and Antiseptics. *Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care*. 2014 Apr 30:573–80. doi: 10.1007/978-1-4614-8948-1_35. PMCID: PMC7120559.
24. Yabuta K, Futamura H, Kawasaki K, Sugiyama H. Impact of H₂O₂ sorption by polymers on the duration of aeration in pharmaceutical decontamination. *J Pharm Sci.* 2020;109(9):2767–2773.
25. Eisner DR, Hubbard A, Eppler K, Tegoulia V, Maa Y-F. Vapor-phase hydrogen peroxide uptake by silicone tubing and primary packaging components during protein drug product aseptic filling: impact of pretreatment and sterilization process. *PDA J Pharm Sci Technol.* 2019;73(4):443–458.
26. Meleties M, et al. Vaporized hydrogen peroxide sterilization in the production of protein therapeutics: uptake and effects on product quality. *J Pharm Sci.* 2023;112(12):2991–3004.
27. Vuylsteke, B., Luyckx, I., & De Lannoy, G. (2019). The diffusion of hydrogen peroxide into the liquid product during filling operations inside vaporous hydrogen Peroxide–Sterilized isolators can be predicted by a mechanistic model. *Journal of Pharmaceutical Sciences*, 108(8), 2527–2533. <https://doi.org/10.1016/j.xphs.2019.03.033>

28. Hui, Ada & Lam, Xanthe & Kuehl, Christopher & Grauschopf, Ulla & Wang, Y.. (2015). Kinetic Modeling of Methionine Oxidation in Monoclonal Antibodies from Hydrogen Peroxide Spiking Studies. *PDA journal of pharmaceutical science and technology* / PDA. 69. 511-25. 10.5731/pdajpst.2015.01059.
29. Chew CC, Khor CH. Optimizing Biological Indicator Placement for Validating High-Efficiency Particulate Air Housing Decontamination. *Appl Biosaf.* 2025 Mar 7;30(1):29-35. doi: 10.1089/apb.2024.0013. PMID: 40151383; PMCID: PMC11937792.
30. McLeod NP, Clifford M, Sutton J. Evaluation of novel process indicators for rapid monitoring of hydrogen peroxide decontamination processes. *PDA J Pharm Sci Technol.* 2017;71(5):393–404.
31. Schachtschneider A, Klein S, Marshall K. Application of enzyme indicators in hydrogen peroxide bi decontamination cycle development: a critical evaluation of indicator variability and correlation to biological indicator results. *PDA J Pharm Sci Technol.* 2022;76(1):34–51
32. Gabbott K. Insights for the use of enzyme indicators in hydrogen peroxide bio-decontamination cycle validation. *PDA J Pharm Sci Technol.* 2026;80(4)
33. Eschlbeck, E., Seeburger, C. and Kulozik, U. (2020), Spore inactivation on solid surfaces by vaporized hydrogen peroxide—Influence of carrier material surface properties. *Journal of Food Science*, 85: 1536-1541. <https://doi.org/10.1111/1750-3841.15086>

Disclaimer

This white paper is intended for informational purposes only and provides a general overview of the scientific, regulatory, and lifecycle considerations associated with biodecontamination of pharmaceutical isolators and other closed or barrier systems. It does not constitute regulatory guidance, validation or engineering advice, or a product specification, nor does it establish specific acceptance criteria or process parameters for any individual application. The selection, development, validation, and ongoing control of a biodecontamination process should be based on the specific system design, technology, materials, load configuration, process conditions, intended use, and applicable regulatory requirements. Readers should consult qualified quality, validation, engineering, microbiological, and regulatory professionals when applying the principles discussed in this paper to a specific facility or process.

